Combination of antibody-drug conjugates and EZH1 and / or EZH2
By combining antibody-drug conjugates with EZH1 and EZH2 inhibitors, the problem of poor anti-tumor effect when used alone is solved, and the ability of anti-tumor drugs to inhibit cancer cell growth and kill in cancer cells is significantly improved. efficiency.
Patent Information
- Application Number
- CN202380036601.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-27
- Filing Date
- 2023-04-26
- Publication Date
- 2024-12-06
AI Technical Summary
Although existing antibody-drug conjugates have anti-tumor effects when used alone, they are difficult to inhibit the growth of cancer cells in various ways and lack better anti-tumor effects.
Specific antibody-drug conjugates were used in combination with EZH1 inhibitors, EZH2 inhibitors and EZH1/2 dual inhibitors to enhance antitumor effects.
Through combined use, the effect of anti-tumor drugs is significantly improved, and it can more effectively inhibit the growth of cancer cells and enhance the accumulation and killing efficiency of drugs in cancer cells.
Smart Images

Figure CN119095624A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a pharmaceutical product, wherein a specific antibody-drug conjugate is administered in combination with an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor, and / or a method of treatment, wherein a specific antibody-drug conjugate is administered to a subject in combination with an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor. Background Art
[0002] The Polycomb family of proteins negatively regulates gene expression through chromatin control mediated by histone modification. Enhancer of zeste homolog 1 / 2 (EZH1 / 2) is the active center of the Polycomb repressive complex 2 (PRC2), which trimethylates histone H3K27. EZH1 and EZH2 compensate for each other's functions and maintain the epigenome in the cell. Inhibition of EZH2 reduces the methylation level of H3K27 throughout the cell; however, this effect is limited by the compensatory effect of EZH1. If EZH1 and EZH2 are inhibited at the same time, methylation is more effectively eliminated (Non-patent reference 1). Abnormalities in the components of PRC2 can cause functional abnormalities in cancer and stem cells. Specifically, abnormalities in the EZH2 gene and its increased expression induce the accumulation of methylated H3K27me3, which is found in many cancers. Research focusing on EZH2 as a new molecular target for cancer has been actively carried out (Non-patent references 2, 3).
[0003] As an example of a compound having EZH1 and / or EZH2 inhibitory activity, the EZH1 / 2 dual inhibitor (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide and a pharmaceutically acceptable salt thereof are known (Patent Reference 1).
[0004] Schlafen 11 (SLFN11), a putative DNA / RNA helicase that is recruited to stressed replication forks and irreversibly triggers replication arrest and cell death, has emerged as a promising predictor of sensitivity to cytotoxic chemotherapies, particularly DNA-damaging agents (DDAs) such as topoisomerase (TOP) I and TOP II (irinotecan and etoposide, respectively), DNA synthesis inhibitors (e.g., gemcitabine), and DNA cross-linking and alkylating agents (e.g., cisplatin) (Non-patent reference 4).
[0005] One study found that EZH1 / 2 inhibitors could reverse the epigenetic mechanism of acquired chemoresistance caused by epigenetic silencing of SLFN11. In this context, inhibition of EZH1 / 2 restored SLFN11 expression and synergized with a variety of DNA damaging agents in vitro and in vivo (Non-patent Reference 5).
[0006] In terms of cancer treatment, it is known that therapies using a combination of multiple anticancer agents are effective, and various studies (regarding combination therapy) have been actively carried out. For example, a patent application discloses that a combination drug containing an EZH1 / 2 dual inhibitor and another agent exerts an excellent anticancer effect (Patent Reference 12). In addition, Phase I and Phase II trials evaluating the safety and tolerability of valmetostam (DS-3201b) (a potent dual EZH1 / 2 inhibitor) in combination with irinotecan in patients with recurrent SCLC are underway (NCT03879798).
[0007] Antibody-drug conjugates (ADCs) containing a cytotoxic drug conjugated to an antibody capable of binding to an antigen expressed on the surface of cancer cells and internalizing the cells can selectively deliver the drug to cancer cells and thus can be expected to cause accumulation of the drug in cancer cells and kill the cancer cells (Non-patent References 6 to 10).
[0008] As such an antibody-drug conjugate, an antibody-drug conjugate containing an antibody and a derivative of exotecan as a topoisomerase I inhibitor as its components is known (Patent References 2 to 10, Non-Patent Documents 11 to 15). In addition, a patent application discloses that the combined expression amount of the hTROP2 gene and the SLFN11 gene at the mRNA level can more accurately identify a subject to whom a drug containing an anti-hTROP2 antibody should be administered (Patent Reference 11).
[0009] However, none of the references describe any test results showing the combined effects of the aforementioned antibody-drug conjugates and EZH1 and / or EZH2 inhibitors or any scientific basis suggesting such test results.
[0010] Citation List
[0011] Patent Literature
[0012] Patent Reference 1: International Publication No. WO2015 / 141616
[0013] Patent Reference 2: International Publication No. WO 2014 / 057687
[0014] Patent Reference 3: International Publication No. WO 2014 / 061277
[0015] Patent Reference 4: International Publication No. WO 2015 / 098099
[0016] Patent Reference 5: International Publication No. WO 2015 / 115091
[0017] Patent Reference 6: International Publication No. WO 2015 / 146132
[0018] Patent Reference 7: International Publication No. WO 2015 / 155976
[0019] Patent Reference 8: International Publication No. WO 2015 / 155998
[0020] Patent Reference 9: International Publication No. WO 2018 / 135501
[0021] Patent Reference 10: International Publication No. WO 2018 / 212136
[0022] Patent Reference 11: International Publication No. WO2020 / 040245
[0023] Patent Reference 12: International Publication No. WO2020 / 111234
[0024] Non-patent literature
[0025] Non-patent reference 1: Shen, X et al., Mol Cell 2008; 32(4): 491-502.
[0026] Non-patent reference 2: Sparmann A, van Lohuizen M., Nat Rev Cancer 2006; 6: 846.
[0027] Non-patent reference 3: Lund, Adams, Copland., Leukemia 2014; 28(1): 44-9.
[0028] Non-patent reference 4: Coleman, N. et al., British Journal of Cancer. (2021) 124: 857-859
[0029] Non-patent reference 5: Poirier, JT et al., Journal of Thoracic Oncology (2020) 15, 4: 520-540
[0030] Non-patent reference 6: Ducry, L. et al., Bioconjugate Chem. (2010) 21, 5-13.
[0031] Non-patent reference 7: Alley, SC et al., Current Opinion in Chemical Biology (2010) 14, 529-537.
[0032] Non-patent reference 8: Damle NK Expert Opin. Biol. Ther. (2004) 4, 1445-1452.
[0033] Non-patent reference 9: Senter PD et al., Nature Biotechnology (2012) 30, 631-637.
[0034] Non-patent reference 10: Burris HA et al., J. Clin. Oncol. (2011) 29(4): 398-405.
[0035] Non-patent reference 11: Ogitani Y. et al., Clinical Cancer Research (2016) 22(20), 5097-5108.
[0036] Non-patent reference 12: Ogitani Y. et al., Cancer Science (2016) 107, 1039-1046.
[0037] Non-patent reference 13: Doi T et al., Lancet Oncol. (2017) 18, 1512-22.
[0038] Non-patent reference 14: Takegawa N et al., Int. J. Cancer (2017) 141, 1682-1689.
[0039] Non-patent reference 15: Yonesaka K et al., Oncogene (2019) 38: 1398-1409. Summary of the invention
[0040] Technical issues
[0041] The antibody-drug conjugate used in the present invention (antibody-drug conjugate containing an exotecan derivative as a component) has been confirmed to exert excellent antitumor effects even as a single agent. However, it is necessary to obtain a treatment method that can inhibit the growth of cancer cells in various ways and exert a more excellent antitumor effect by combining an antibody-drug conjugate with another anticancer agent having a different mechanism of action.
[0042] An object of the present invention is to provide a pharmaceutical product for administering a specific antibody-drug conjugate in combination with an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor, and / or therapeutic uses and methods, wherein the specific antibody-drug conjugate is administered to a subject in combination with an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor.
[0043] Solution to the problem
[0044] As a result of diligent studies to solve the above problems, the inventors of the present invention have found that combined administration of a specific antibody-drug conjugate and an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor, and an EZH1 / 2 dual inhibitor exhibits an excellent combination effect, thereby completing the present invention.
[0045] Therefore, the present invention provides the following [1] to
[261] .
[0046] [1] A pharmaceutical product comprising an antibody-drug conjugate for combined administration and an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor, wherein
[0047] The antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker is represented by the following formula:
[0048] [Formula 1]
[0049]
[0050] Where A represents the connection position with the antibody,
[0051] Conjugation to the antibody is via a thioether bond.
[0052] [2] The pharmaceutical product according to [1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody or an anti-MUC1 antibody.
[0053] [3] The pharmaceutical product according to [2], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0054] [4] The pharmaceutical product according to [3], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:2.
[0055] [5] The pharmaceutical product according to [3], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO:1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2.
[0056] [6] The pharmaceutical product according to [3], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:1, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:2.
[0057] [7] The pharmaceutical product according to [3], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1; and the light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:2.
[0058] [8] The pharmaceutical product according to any one of [3] to [7], wherein the antibody-drug conjugate is represented by the following formula:
[0059] [Formula 2]
[0060]
[0061] wherein “antibody” indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0062] [9] The pharmaceutical product according to [2], wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
[0063]
[10] The pharmaceutical product according to [9], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:3, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:4.
[0064]
[11] The pharmaceutical product according to
[10] , wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0065]
[12] The pharmaceutical product according to any one of [9] to
[11] , wherein the antibody-drug conjugate is represented by the following formula:
[0066] [Formula 3]
[0067]
[0068] wherein “antibody” indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0069]
[13] The pharmaceutical product according to [2], wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
[0070]
[14] The pharmaceutical product according to
[13] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6.
[0071]
[15] The pharmaceutical product according to
[13] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6.
[0072]
[16] The pharmaceutical product according to
[13] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6.
[0073]
[17] The pharmaceutical product according to
[16] , wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0074]
[18] The pharmaceutical product according to any one of
[13] to
[17] , wherein the antibody-drug conjugate is represented by the following formula:
[0075] [Formula 4]
[0076]
[0077] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0078]
[19] The pharmaceutical product according to [2], wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
[0079]
[20] The pharmaceutical product according to
[19] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8.
[0080]
[21] The pharmaceutical product according to
[20] , wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0081]
[22] The pharmaceutical product according to any one of
[19] to
[21] , wherein the antibody-drug conjugate is represented by the following formula:
[0082] [Formula 5]
[0083]
[0084] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0085]
[23] The pharmaceutical product according to [2], wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[0086]
[24] The pharmaceutical product according to
[23] , wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10.
[0087]
[25] The pharmaceutical product according to
[24] , wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0088]
[26] The pharmaceutical product according to any one of
[23] to
[25] , wherein the antibody-drug conjugate is represented by the following formula:
[0089] [Formula 6]
[0090]
[0091] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0092]
[27] The pharmaceutical product according to [2], wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[0093]
[28] The pharmaceutical product according to
[27] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12.
[0094]
[29] The pharmaceutical product according to
[28] , wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0095]
[30] The pharmaceutical product according to any one of
[27] to
[29] , wherein the antibody-drug conjugate is represented by the following formula:
[0096] [Formula 7]
[0097]
[0098] wherein “antibody” indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0099]
[31] The pharmaceutical product according to [2], wherein the antibody in the antibody-drug conjugate is an anti-MUC1 antibody.
[0100]
[32] The pharmaceutical product according to
[31] , wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0101]
[33] The pharmaceutical product according to
[32] , wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0102]
[34] The pharmaceutical product according to
[31] , wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0103]
[35] The pharmaceutical product according to
[34] , wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0104]
[36] The pharmaceutical product according to any one of
[31] to
[35] , wherein the antibody-drug conjugate is represented by the following formula:
[0105] [Formula 8]
[0106]
[0107] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0108]
[37] The pharmaceutical product according to any one of [1] to [8], wherein the antibody-drug conjugate is trastuzumab deruxtecan (DS-8201a).
[0109]
[38] The pharmaceutical product according to any one of [1] to [2] and
[13] to
[18] , wherein the antibody-drug conjugate is datopotamab deruxtecan (DS-1062).
[0110]
[39] The pharmaceutical product according to any one of [1] to
[38] , wherein the inhibitor is an EZH2 inhibitor.
[0111]
[40] The pharmaceutical product according to
[39] , wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
[0112]
[41] The pharmaceutical product according to any one of [1] to
[38] , wherein the inhibitor is an EZH1 / 2 dual inhibitor.
[0113]
[42] The pharmaceutical product according to
[41] , wherein the inhibitor is valemetostat or a pharmaceutically acceptable salt thereof.
[0114]
[43] The pharmaceutical product according to
[41] or
[42] , wherein the inhibitor is valmetostostat tosylate.
[0115]
[44] The pharmaceutical product according to any one of [1] to
[43] , wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously or at different times.
[0116]
[45] The pharmaceutical product according to any one of [1] to
[44] and
[257] , wherein the pharmaceutical product is used to treat at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, bile duct cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma.
[0117]
[46] The pharmaceutical product according to
[45] , wherein the pharmaceutical product is used to treat breast cancer.
[0118]
[47] The pharmaceutical product according to
[46] , wherein the pharmaceutical product is used to treat triple-negative breast cancer.
[0119]
[48] The pharmaceutical product according to
[45] , wherein the pharmaceutical product is used to treat gastric cancer.
[0120]
[49] The pharmaceutical product according to
[45] , wherein the pharmaceutical product is used to treat ovarian cancer.
[0121]
[50] The pharmaceutical product according to
[45] , wherein the pharmaceutical product is used to treat lung cancer.
[0122]
[51] The pharmaceutical product according to
[45] , wherein the pharmaceutical product is used to treat pancreatic cancer.
[0123]
[52] A method of treating a subject in need of treatment comprising administering an antibody-drug conjugate in combination with an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor, and an EZH1 / 2 dual inhibitor, wherein the antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker is represented by the following formula:
[0124] [Formula 9]
[0125]
[0126] Where A represents the connection position with the antibody,
[0127] Conjugation to the antibody is via a thioether bond.
[0128]
[53] The method of
[52] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody or an anti-MUC1 antibody.
[0129]
[54] The treatment method of
[53] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0130]
[55] The method of
[54] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:2.
[0131]
[56] The method of
[54] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO:1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2.
[0132]
[57] The method of
[54] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:1, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:2.
[0133]
[58] The method of
[54] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1, and the light chain consisting of an amino acid sequence represented by amino acid residues 1 to 214 of SEQ ID NO:2.
[0134]
[59] The method of any one of
[54] to
[58] , wherein the antibody-drug conjugate is represented by the following formula:
[0135] [Formula 10]
[0136]
[0137] wherein “antibody” indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0138]
[60] The treatment method of
[53] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
[0139]
[61] The method of
[60] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:3, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:4.
[0140]
[62] The method of treatment according to
[61] , wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0141]
[63] The method of any one of
[60] to
[62] , wherein the antibody-drug conjugate is represented by the following formula:
[0142] [Formula 11]
[0143]
[0144] wherein “antibody” indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0145]
[64] The treatment method according to
[53] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
[0146]
[65] The method of
[64] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6.
[0147]
[66] The method of
[64] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6.
[0148]
[67] The method of
[64] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6.
[0149]
[68] The treatment method according to
[67] , wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0150]
[69] The method of any one of
[64] to
[68] , wherein the antibody-drug conjugate is represented by the following formula:
[0151] [Formula 12]
[0152]
[0153] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0154]
[70] The treatment method according to
[53] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
[0155]
[71] The method of
[70] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8.
[0156]
[72] The treatment method according to
[71] , wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0157]
[73] The method of any one of
[70] to
[72] , wherein the antibody-drug conjugate is represented by the following formula:
[0158] [Formula 13]
[0159]
[0160] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0161]
[74] The method of
[53] , wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[0162]
[75] The method of
[74] , wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10.
[0163]
[76] The method of treatment according to
[75] , wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0164]
[77] The method of any one of
[74] to
[76] , wherein the antibody-drug conjugate is represented by the following formula:
[0165] [Formula 14]
[0166]
[0167] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0168]
[78] The treatment method according to
[53] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[0169]
[79] The method of
[78] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12.
[0170]
[80] The treatment method according to
[79] , wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0171]
[81] The method of any one of
[78] to
[80] , wherein the antibody-drug conjugate is represented by the following formula:
[0172] [Formula 15]
[0173]
[0174] wherein “antibody” indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0175]
[82] The method according to
[53] , wherein the antibody in the antibody-drug conjugate is an anti-MUC1 antibody.
[0176]
[83] The method according to
[82] , wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0177]
[84] The method of
[83] , wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0178]
[85] The method according to
[82] , wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0179]
[86] The method of
[85] , wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0180]
[87] The method according to any one of
[82] to
[86] , wherein the antibody-drug conjugate is represented by the following formula:
[0181] [Formula 16]
[0182]
[0183] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0184]
[88] The treatment method according to any one of
[52] to
[59] , wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
[0185]
[89] The method of any one of
[52] to
[53] and
[64] to
[69] , wherein the antibody-drug conjugate is dedabrutinib (DS-1062).
[0186]
[90] The method of any one of
[52] to
[89] , wherein the inhibitor is an EZH2 inhibitor.
[0187]
[91] The method of treatment according to
[90] , wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
[0188]
[92] The method of any one of
[52] to
[89] , wherein the inhibitor is an EZH1 / 2 dual inhibitor.
[0189]
[93] The method of
[92] , wherein the inhibitor is vametadostat or a pharmaceutically acceptable salt thereof.
[0190]
[94] The method of treatment according to
[92] or
[93] , wherein the inhibitor is valmetostostat tosylate.
[0191]
[95] The method of any one of
[52] to
[94] , wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously or at different times.
[0192]
[96] A method according to any one of
[52] to
[95] and
[258] , wherein the method is used to treat at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, bile duct cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma.
[0193]
[97] The method according to
[96] , wherein the method is used to treat breast cancer.
[0194]
[98] The treatment method according to
[97] , wherein the treatment method is used to treat triple-negative breast cancer.
[0195]
[99] The method according to
[96] , wherein the method is used to treat gastric cancer.
[0196]
[100] The method according to
[96] , wherein the method is used to treat ovarian cancer.
[0197]
[101] The method according to
[96] , wherein the method is used to treat lung cancer.
[0198]
[102] The method according to
[96] , wherein the method is used to treat pancreatic cancer.
[0199]
[103] An antibody-drug conjugate for use in a method of treating a disease, wherein the method comprises administering the antibody-drug conjugate in combination with an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor, and an EZH1 / 2 dual inhibitor, wherein the antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker in the antibody-drug conjugate is represented by the following formula:
[0200] [Formula 17]
[0201]
[0202] Where A represents the connection position with the antibody,
[0203] Conjugation to the antibody is via a thioether bond.
[0204]
[104] An antibody-drug conjugate for the use according to
[103] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody or an anti-MUC1 antibody.
[0205]
[105] An antibody-drug conjugate for the use according to
[104] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0206]
[106] An antibody-drug conjugate for the use according to
[105] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:2.
[0207]
[107] An antibody-drug conjugate for the use according to
[105] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO:1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2.
[0208]
[108] An antibody-drug conjugate for the use according to
[105] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:1, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:2.
[0209]
[109] An antibody-drug conjugate for the use according to
[105] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1; and the light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:2.
[0210]
[110] An antibody-drug conjugate for use according to any one of
[105] to
[109] , wherein the antibody-drug conjugate is represented by the following formula:
[0211] [Formula 18]
[0212]
[0213] wherein “antibody” indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0214]
[111] The antibody-drug conjugate for the use according to
[104] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
[0215]
[112] An antibody-drug conjugate for the use according to
[111] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:3, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:4.
[0216]
[113] An antibody-drug conjugate for use according to
[112] , wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0217]
[114] An antibody-drug conjugate for use according to any one of
[111] to
[113] , wherein the antibody-drug conjugate is represented by the following formula:
[0218] [Formula 19]
[0219]
[0220] wherein “antibody” indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0221]
[115] The antibody-drug conjugate for the use according to
[104] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
[0222]
[116] An antibody-drug conjugate for the use according to
[115] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6.
[0223]
[117] An antibody-drug conjugate for the use according to
[115] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6.
[0224]
[118] An antibody-drug conjugate for the use according to
[115] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6.
[0225]
[119] The antibody-drug conjugate for use according to
[118] , wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0226]
[120] An antibody-drug conjugate for use according to any one of
[115] to
[119] , wherein the antibody-drug conjugate is represented by the following formula:
[0227] [Formula 20]
[0228]
[0229] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0230]
[121] The antibody-drug conjugate for the use according to
[104] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
[0231]
[122] An antibody-drug conjugate for the use according to
[121] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8.
[0232]
[123] An antibody-drug conjugate for use according to
[122] , wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0233]
[124] An antibody-drug conjugate for use according to any one of
[121] to
[123] , wherein the antibody-drug conjugate is represented by the following formula:
[0234] [Formula 21]
[0235]
[0236] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0237]
[125] The antibody-drug conjugate for use according to
[104] , wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[0238]
[126] An antibody-drug conjugate for the use according to
[125] , wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10.
[0239]
[127] The antibody-drug conjugate for use according to
[126] , wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0240]
[128] An antibody-drug conjugate for use according to any one of
[125] to
[127] , wherein the antibody-drug conjugate is represented by the following formula:
[0241] [Formula 22]
[0242]
[0243] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0244]
[129] The antibody-drug conjugate for use according to
[104] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[0245]
[130] An antibody-drug conjugate for the use according to
[129] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12.
[0246]
[131] The antibody-drug conjugate for use according to
[130] , wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0247]
[132] An antibody-drug conjugate for use according to any one of
[129] to
[131] , wherein the antibody-drug conjugate is represented by the following formula:
[0248] [Formula 23]
[0249]
[0250] wherein “antibody” indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0251]
[133] The antibody-drug conjugate for use according to
[104] , wherein the antibody in the antibody-drug conjugate is an anti-MUC1 antibody.
[0252]
[134] An antibody-drug conjugate for use according to
[133] , wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0253]
[135] The antibody-drug conjugate for use according to
[134] , wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0254]
[136] An antibody-drug conjugate for use according to
[133] , wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0255]
[137] The antibody-drug conjugate for use according to
[136] , wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0256]
[138] An antibody-drug conjugate for use according to any one of
[133] to
[137] , wherein the antibody-drug conjugate is represented by the following formula:
[0257] [Equation 24]
[0258]
[0259] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0260]
[139] An antibody-drug conjugate for use according to any one of
[103] to
[110] , wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
[0261]
[140] An antibody-drug conjugate for use according to any one of
[103] to
[104] and
[115] to
[120] , wherein the antibody-drug conjugate is dedabrutinib (DS-1062).
[0262]
[141] An antibody-drug conjugate for use according to any one of
[103] to
[140] , wherein the inhibitor is an EZH2 inhibitor.
[0263]
[142] The antibody-drug conjugate for use according to
[141] , wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
[0264]
[143] An antibody-drug conjugate for use according to any one of
[103] to
[140] , wherein the inhibitor is an EZH1 / 2 dual inhibitor.
[0265]
[144] The antibody-drug conjugate for use according to
[143] , wherein the inhibitor is vametadostat or a pharmaceutically acceptable salt thereof.
[0266]
[145] An antibody-drug conjugate for use according to
[143] or
[144] , wherein the inhibitor is valmetostostat tosylate.
[0267]
[146] An antibody-drug conjugate for use according to any one of
[103] to
[145] , wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously or at different times.
[0268]
[147] An antibody-drug conjugate for use according to any one of
[103] to
[146] and
[259] , wherein the disease is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, bile duct cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma.
[0269]
[148] The antibody-drug conjugate for use according to
[147] , wherein the disease is breast cancer.
[0270]
[149] The antibody-drug conjugate for use according to
[148] , wherein the disease is triple-negative breast cancer.
[0271]
[150] The antibody-drug conjugate for use according to
[147] , wherein the disease is gastric cancer.
[0272]
[151] The antibody-drug conjugate for use according to
[147] , wherein the disease is ovarian cancer.
[0273]
[152] The antibody-drug conjugate for use according to
[147] , wherein the disease is lung cancer.
[0274]
[153] The antibody-drug conjugate for use according to
[147] , wherein the disease is pancreatic cancer.
[0275]
[154] Use of an antibody-drug conjugate or an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor for preparing a medicament for treating a disease by administering the antibody-drug conjugate and the inhibitor in combination, wherein the antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker represented by the following formula in the antibody-drug conjugate is:
[0276] [Formula 25]
[0277]
[0278] Where A represents the connection position with the antibody,
[0279] Conjugation to the antibody is via a thioether bond.
[0280]
[155] The use according to
[154] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody or an anti-MUC1 antibody.
[0281]
[156] The use according to
[155] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0282]
[157] The use according to
[156] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:2.
[0283]
[158] The use according to
[156] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO:1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2.
[0284]
[159] The use according to
[156] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consists of the amino acid sequence shown in SEQ ID NO:1, and the light chain consists of the amino acid sequence shown in SEQ ID NO:2.
[0285]
[160] The use according to
[156] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1; and the light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:2.
[0286]
[161] The use according to any one of
[156] to
[160] ,
[0287] The antibody-drug conjugate is represented by the following formula:
[0288] [Equation 26]
[0289]
[0290] wherein “antibody” indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0291]
[162] The use according to
[155] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
[0292]
[163] The use according to
[162] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consists of the amino acid sequence shown in SEQ ID NO:3, and the light chain consists of the amino acid sequence shown in SEQ ID NO:4.
[0293]
[164] The use according to
[163] , wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0294]
[165] The use according to any one of
[162] to
[164] , wherein the antibody-drug conjugate is represented by the following formula:
[0295] [Formula 27]
[0296]
[0297] wherein “antibody” indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0298]
[166] The use according to
[155] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
[0299]
[167] The use according to
[166] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6.
[0300]
[168] The use according to
[166] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6.
[0301]
[169] The use according to
[166] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6.
[0302]
[170] The use according to
[169] , wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0303]
[171] The use according to any one of
[166] to
[170] , wherein the antibody-drug conjugate is represented by the following formula:
[0304] [Equation 28]
[0305]
[0306] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0307]
[172] The use according to
[155] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
[0308]
[173] The use according to
[172] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8.
[0309]
[174] The use according to
[173] , wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0310]
[175] The use according to any one of
[172] to
[174] , wherein the antibody-drug conjugate is represented by the following formula:
[0311] [Formula 29]
[0312]
[0313] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0314]
[176] The use according to
[155] , wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[0315]
[177] The use according to
[176] , wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10.
[0316]
[178] The use according to
[177] , wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0317]
[179] The use according to any one of
[176] to
[178] , wherein the antibody-drug conjugate is represented by the following formula:
[0318] [Formula 30]
[0319]
[0320] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0321]
[180] The use according to
[155] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[0322]
[181] The use according to
[180] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12.
[0323]
[182] The use according to
[181] , wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0324]
[183] The use according to any one of
[180] to
[182] , wherein the antibody-drug conjugate is represented by the following formula:
[0325] [Equation 31]
[0326]
[0327] wherein “antibody” indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0328]
[184] The use according to
[155] , wherein the antibody in the antibody-drug conjugate is an anti-MUC1 antibody.
[0329]
[185] The use according to
[184] , wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0330]
[186] The use according to
[185] , wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0331]
[187] The use according to
[184] , wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0332]
[188] The use according to
[187] , wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0333]
[189] The use according to any one of
[184] to
[188] , wherein the antibody-drug conjugate is represented by the following formula:
[0334] [Formula 32]
[0335]
[0336] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0337]
[190] The use according to any one of
[154] to
[161] , wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
[0338]
[191] The use according to any one of
[154] to
[155] and
[166] to
[171] , wherein the antibody-drug conjugate is dedabrafenib (DS-1062).
[0339]
[192] The use according to any one of
[154] to
[191] , wherein the inhibitor is an EZH2 inhibitor.
[0340]
[193] The use according to
[192] , wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
[0341]
[194] The use according to any one of
[154] to
[191] , wherein the inhibitor is an EZH1 / 2 dual inhibitor.
[0342]
[195] The use according to
[194] , wherein the inhibitor is vametadostat or a pharmaceutically acceptable salt thereof.
[0343]
[196] The use according to
[194] or
[195] , wherein the inhibitor is valmetostostat tosylate.
[0344]
[197] The use according to any one of
[154] to
[196] , wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously or at different times.
[0345]
[198] The use according to any one of
[154] to
[197] and
[260] , wherein the disease is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, bile duct cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma.
[0346]
[199] The use according to
[198] , wherein the disease is breast cancer.
[0347]
[200] The use according to
[199] , wherein the disease is triple-negative breast cancer.
[0348]
[201] The use according to
[198] , wherein the disease is gastric cancer.
[0349]
[202] The use according to
[198] , wherein the disease is ovarian cancer.
[0350]
[203] The use according to
[198] , wherein the disease is lung cancer.
[0351]
[204] The use according to
[198] , wherein the disease is pancreatic cancer.
[0352]
[205] An inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor for use in a method for treating a disease, wherein the method comprises administering the inhibitor in combination with an antibody-drug conjugate, wherein the antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker in the antibody-drug conjugate is represented by the following formula:
[0353] [Formula 33]
[0354]
[0355] Where A represents the connection position with the antibody,
[0356] Conjugation to the antibody is via a thioether bond.
[0357]
[206] An inhibitor for use according to
[205] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody or an anti-MUC1 antibody.
[0358]
[207] The inhibitor for use according to
[206] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0359]
[208] An inhibitor for use according to
[207] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:2.
[0360]
[209] An inhibitor for the use according to
[207] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO:1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2.
[0361]
[210] An inhibitor for the use according to
[207] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:1, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:2.
[0362]
[211] An inhibitor for the use according to
[207] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1; and the light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:2.
[0363]
[212] The inhibitor for use according to any one of
[207] to
[211] , wherein the antibody-drug conjugate is represented by the following formula:
[0364] [Equation 34]
[0365]
[0366] wherein “antibody” indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0367]
[213] The inhibitor for use according to
[206] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
[0368]
[214] An inhibitor for the use according to
[213] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:3, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:4.
[0369]
[215] An inhibitor for use according to
[214] , wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0370]
[216] An inhibitor for use according to any one of
[213] to
[215] , wherein the antibody-drug conjugate is represented by the following formula:
[0371] [Formula 35]
[0372]
[0373] wherein “antibody” indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0374]
[217] The inhibitor for use according to
[206] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
[0375]
[218] An inhibitor for use according to
[217] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6.
[0376]
[219] An inhibitor for the use according to
[217] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6.
[0377]
[220] An inhibitor for use according to
[217] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6.
[0378]
[221] The inhibitor for use according to
[220] , wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0379]
[222] An inhibitor for use according to any one of
[217] to
[221] , wherein the antibody-drug conjugate is represented by the following formula:
[0380] [Equation 36]
[0381]
[0382] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0383]
[223] The inhibitor for use according to
[206] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
[0384]
[224] An inhibitor for use according to
[223] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8.
[0385]
[225] An inhibitor for use according to
[224] , wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0386]
[226] An inhibitor for use according to any one of
[223] to
[225] , wherein the antibody-drug conjugate is represented by the following formula:
[0387] [Formula 37]
[0388]
[0389] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0390]
[227] The inhibitor for use according to
[206] , wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[0391]
[228] An inhibitor for use according to
[227] , wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10.
[0392]
[229] The inhibitor for use according to
[228] , wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0393]
[230] An inhibitor for use according to any one of
[227] to
[229] , wherein the antibody-drug conjugate is represented by the following formula:
[0394] [Equation 38]
[0395]
[0396] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0397]
[231] The inhibitor for use according to
[206] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[0398]
[232] An inhibitor for use according to
[231] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12.
[0399]
[233] The inhibitor for use according to
[232] , wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0400]
[234] An inhibitor for use according to any one of
[231] to
[233] , wherein the anti-CDH6 antibody-drug conjugate is represented by the following formula:
[0401] [Equation 39]
[0402]
[0403] wherein “antibody” indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0404]
[235] The inhibitor for use according to
[206] , wherein the antibody in the antibody-drug conjugate is an anti-MUC1 antibody.
[0405]
[236] An inhibitor for use according to
[235] , wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0406]
[237] The inhibitor for use according to
[236] , wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0407]
[238] An inhibitor for use according to
[235] , wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0408]
[239] The inhibitor for use according to
[238] , wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0409]
[240] An inhibitor for use according to any one of
[235] to
[239] , wherein the antibody-drug conjugate is represented by the following formula:
[0410] [Formula 40]
[0411]
[0412] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0413]
[241] An inhibitor for use according to any one of
[205] to
[212] , wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
[0414]
[242] An inhibitor for use according to any one of
[205] to
[206] and
[217] to
[222] , wherein the antibody-drug conjugate is dedabrutinib (DS-1062).
[0415]
[243] An inhibitor for use according to any one of
[205] to
[242] , wherein the inhibitor is an EZH2 inhibitor.
[0416]
[244] The inhibitor for use according to
[243] , wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
[0417]
[245] An inhibitor for use according to any one of
[205] to
[242] , wherein the inhibitor is an EZH1 / 2 dual inhibitor.
[0418]
[246] The inhibitor for use according to
[245] , wherein the inhibitor is vametadostat or a pharmaceutically acceptable salt thereof.
[0419]
[247] An inhibitor for use according to
[245] or
[246] , wherein the inhibitor is valmetostostat tosylate.
[0420]
[248] An inhibitor for use according to any one of
[205] to
[247] , wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously or at different times.
[0421]
[249] An inhibitor for use according to any one of
[205] to
[248] and
[261] , wherein the disease is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, bile duct cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma.
[0422]
[250] An inhibitor for use according to
[249] , wherein the disease is breast cancer.
[0423]
[251] An inhibitor for use according to
[250] , wherein the disease is triple-negative breast cancer.
[0424]
[252] An inhibitor for use according to
[249] , wherein the disease is gastric cancer.
[0425]
[253] An inhibitor for use according to
[249] , wherein the disease is ovarian cancer.
[0426]
[254] An inhibitor for use according to
[249] , wherein the disease is lung cancer.
[0427]
[255] An inhibitor for use according to
[249] , wherein the disease is pancreatic cancer.
[0428]
[256] The pharmaceutical product according to any one of [1] to
[51] and
[257] , wherein the pharmaceutical product is a pharmaceutical composition.
[0429]
[257] The pharmaceutical product according to any one of [1] to
[44] , wherein the pharmaceutical product is used to treat cancer.
[0430]
[258] The method of any one of
[52] to
[95] , wherein the method is used to treat cancer.
[0431]
[259] An antibody-drug conjugate for use according to any one of
[103] to
[146] , wherein the disease is cancer.
[0432]
[260] The use according to any one of
[154] to
[197] , wherein the disease is cancer.
[0433]
[261] An inhibitor for use according to any one of
[205] to
[248] , wherein the disease is cancer.
[0434] Other embodiments of the present invention are described below.
[0435] [1-1] A pharmaceutical product comprising an antibody-drug conjugate for combined administration and an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor, and an EZH1 / 2 dual inhibitor, wherein
[0436] The antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker is represented by the following formula:
[0437] [Formula 41]
[0438]
[0439] Where A represents the connection position with the antibody,
[0440] Conjugation to the antibody is via a thioether bond.
[0441] [2-1] The pharmaceutical product according to [1-1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody, an anti-MUC1 antibody or an anti-CD37 antibody.
[0442] [3-1] The pharmaceutical product according to [2-1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0443] [4-1] The pharmaceutical product according to [3-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:2.
[0444] [5-1] The pharmaceutical product according to [3-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO:1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2.
[0445] [6-1] The pharmaceutical product according to [3-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consists of the amino acid sequence shown in SEQ ID NO:1, and the light chain consists of the amino acid sequence shown in SEQ ID NO:2.
[0446] [7-1] The pharmaceutical product according to [3-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1; and the light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:2.
[0447] [8-1] The pharmaceutical product according to any one of [3-1] to [7-1], wherein the antibody-drug conjugate is represented by the following formula:
[0448] [Formula 42]
[0449]
[0450] wherein “antibody” indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0451] [9-1] The pharmaceutical product according to [2-1], wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
[0452] [A1] The pharmaceutical product according to [9-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 35 of SEQ ID NO:3, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 50 to 65 of SEQ ID NO:3, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 98 to 106 of SEQ ID NO:3; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 24 to 39 of SEQ ID NO:4, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 56 to 62 of SEQ ID NO:4, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 95 to 103 of SEQ ID NO:4.
[0453] [A2] The pharmaceutical product according to [9-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 117 of SEQ ID NO:3; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO:4.
[0454] [10-1] The pharmaceutical product according to [9-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consists of the amino acid sequence shown in SEQ ID NO:3, and the light chain consists of the amino acid sequence shown in SEQ ID NO:4.
[0455] [11-1] The pharmaceutical product according to [10-1], wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0456] [12-1] The pharmaceutical product according to any one of [9-1] to [11-1] and [A1] to [A2], wherein the antibody-drug conjugate is represented by the following formula:
[0457] [Formula 43]
[0458]
[0459] wherein “antibody” indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0460] [13-1] The pharmaceutical product according to [2-1], wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
[0461] [14-1] The pharmaceutical product according to [13-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6.
[0462] [15-1] The pharmaceutical product according to [13-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6.
[0463] [16-1] The pharmaceutical product according to [13-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain is composed of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6.
[0464] [17-1] The pharmaceutical product according to [16-1], wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0465] [18-1] The pharmaceutical product according to any one of [13-1] to [17-1], wherein the antibody-drug conjugate is represented by the following formula:
[0466] [Formula 44]
[0467]
[0468] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0469] [19-1] The pharmaceutical product according to [2-1], wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
[0470] [20-1] The pharmaceutical product according to [19-1], wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain is composed of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8.
[0471] [21-1] The pharmaceutical product according to [20-1], wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0472] [22-1] The pharmaceutical product according to any one of [19-1] to [21-1], wherein the antibody-drug conjugate is represented by the following formula:
[0473] [Formula 45]
[0474]
[0475] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0476] [23-1] The pharmaceutical product according to [2-1], wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[0477] [24-1] The pharmaceutical product according to [23-1], wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10.
[0478] [25-1] The pharmaceutical product according to [24-1], wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0479] [26-1] The pharmaceutical product according to any one of [23-1] to [25-1], wherein the antibody-drug conjugate is represented by the following formula:
[0480] [Formula 46]
[0481]
[0482] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0483] [27-1] The pharmaceutical product according to [2-1], wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[0484] [28-1] The pharmaceutical product according to [27-1], wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; and the light chain is composed of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12.
[0485] [29-1] The pharmaceutical product according to [28-1], wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0486] [30-1] The pharmaceutical product according to any one of [27-1] to [29-1], wherein the antibody-drug conjugate is represented by the following formula:
[0487] [Formula 47]
[0488]
[0489] wherein “antibody” indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0490] [31-1] The pharmaceutical product according to [2-1], wherein the antibody in the antibody-drug conjugate is an anti-MUC1 antibody.
[0491] [32-1] The pharmaceutical product according to [31-1], wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0492] [33-1] The pharmaceutical product according to [32-1], wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0493] [34-1] The pharmaceutical product according to [31-1], wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0494] [35-1] The pharmaceutical product according to [34-1], wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0495] [36-1] The pharmaceutical product according to any one of [31-1] to [35-1], wherein the antibody-drug conjugate is represented by the following formula:
[0496] [Formula 48]
[0497]
[0498] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0499] [B1] The pharmaceutical product according to [2-1], wherein the antibody in the antibody-drug conjugate is an anti-CD37 antibody.
[0500] [B2] The pharmaceutical product according to [B1], wherein the anti-CD37 antibody is an antibody selected from the group consisting of:
[0501] (a) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 16; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19,
[0502] (b) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 17; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19, and
[0503] (c) An antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO:18; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO:19.
[0504] [B3] The pharmaceutical product according to [B1], wherein the anti-CD37 antibody is an antibody selected from the group consisting of:
[0505] (d) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 16; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19,
[0506] (e) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 17; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19, and
[0507] (f) An antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0508] [B4] The pharmaceutical product according to [B1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:16; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0509] [B5] The pharmaceutical product according to [B4], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0510] [B6] The pharmaceutical product according to [B4] or [B5], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0511] [B7] The pharmaceutical product according to [B1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:17; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0512] [B8] The pharmaceutical product according to [B7], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0513] [B9] The pharmaceutical product according to [B7] or [B8], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0514] [B10] The pharmaceutical product according to [B1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0515] [B11] The pharmaceutical product according to [B10], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0516] [B12] The pharmaceutical product according to [B10] or [B11], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0517] [B13] The pharmaceutical product according to any one of [B1] to [B12], wherein the antibody-drug conjugate is represented by the following formula:
[0518] [Formula 49]
[0519]
[0520] wherein “antibody” indicates an anti-CD37 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0521] [37-1] The pharmaceutical product according to any one of [1-1] to [8-1], wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
[0522] [38-1] The pharmaceutical product according to any one of [1-1] to [2-1] and [13-1] to [18-1], wherein the antibody-drug conjugate is dedabrutinib (DS-1062).
[0523] [39-1] The pharmaceutical product according to any one of [1-1] to [38-1], [A1] to [A2] and [B1] to [B13], wherein the inhibitor is an EZH2 inhibitor.
[0524] [40-1] The pharmaceutical product according to [39-1], wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
[0525] [41-1] The pharmaceutical product according to any one of [1-1] to [38-1], [A1] to [A2] and [B1] to [B13], wherein the inhibitor is an EZH1 / 2 dual inhibitor.
[0526] [42-1] The pharmaceutical product according to [41-1], wherein the inhibitor is vametadostat or a pharmaceutically acceptable salt thereof.
[0527] [43-1] The pharmaceutical product according to [41-1] or [42-1], wherein the inhibitor is valmetostostat tosylate.
[0528] [44-1] The pharmaceutical product according to any one of [1-1] to [43-1], [A1] to [A2] or [B1] to [B13], wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously or at different times.
[0529] [45-1] A pharmaceutical product according to any one of [1-1] to [44-1], [A1] to [A2], [B1] to [B13] or [257-1], wherein the pharmaceutical product is used to treat at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, bile duct cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma.
[0530] [46-1] The pharmaceutical product according to [45-1], wherein the pharmaceutical product is used to treat breast cancer.
[0531] [47-1] The pharmaceutical product according to [46-1], wherein the pharmaceutical product is used to treat triple-negative breast cancer.
[0532] [48-1] The pharmaceutical product according to [45-1], wherein the pharmaceutical product is used to treat gastric cancer.
[0533] [49-1] The pharmaceutical product according to [45-1], wherein the pharmaceutical product is used to treat ovarian cancer.
[0534] [50-1] The pharmaceutical product according to [45-1], wherein the pharmaceutical product is used to treat lung cancer.
[0535] [51-1] The pharmaceutical product according to [45-1], wherein the pharmaceutical product is used to treat pancreatic cancer.
[0536] [52-1] A method of treating a subject in need of treatment comprising administering an antibody-drug conjugate in combination with an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor, and an EZH1 / 2 dual inhibitor, wherein the antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker is represented by the following formula:
[0537] [Formula 50]
[0538]
[0539] Where A represents the connection position with the antibody,
[0540] Conjugation to the antibody is via a thioether bond.
[0541] [53-1] The treatment method according to [52-1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody, an anti-MUC1 antibody or an anti-CD37 antibody.
[0542] [54-1] The treatment method according to [53-1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0543] [55-1] The method according to [54-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:2.
[0544] [56-1] The method according to [54-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO:1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2.
[0545] [57-1] The method according to [54-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of the amino acid sequence shown in SEQ ID NO:1, and the light chain is composed of the amino acid sequence shown in SEQ ID NO:2.
[0546] [58-1] The method of [54-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1, and the light chain is composed of an amino acid sequence represented by amino acid residues 1 to 214 of SEQ ID NO:2.
[0547] [59-1] The method of any one of [54-1] to [58-1], wherein the antibody-drug conjugate is represented by the following formula:
[0548] [Formula 51]
[0549]
[0550] wherein “antibody” indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0551] [60-1] The treatment method according to [53-1], wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
[0552] [C1] The method according to [60-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 35 of SEQ ID NO:3, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 50 to 65 of SEQ ID NO:3, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 98 to 106 of SEQ ID NO:3; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 24 to 39 of SEQ ID NO:4, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 56 to 62 of SEQ ID NO:4, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 95 to 103 of SEQ ID NO:4.
[0553] [C2] The method according to [60-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 117 of SEQ ID NO:3; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO:4.
[0554] [61-1] The method according to [60-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of the amino acid sequence shown in SEQ ID NO:3, and the light chain is composed of the amino acid sequence shown in SEQ ID NO:4.
[0555] [62-1] The treatment method according to [61-1], wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0556] [63-1] The method of any one of [60-1] to [62-1] or [C1] to [C2], wherein the antibody-drug conjugate is represented by the following formula:
[0557] [Formula 52]
[0558]
[0559] wherein “antibody” indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0560] [64-1] The treatment method according to [53-1], wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
[0561] [65-1] The method according to [64-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6.
[0562] [66-1] The method according to [64-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6.
[0563] [67-1] The method of [64-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain is composed of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6.
[0564] [68-1] The treatment method according to [67-1], wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0565] [69-1] The method of any one of [64-1] to [68-1], wherein the antibody-drug conjugate is represented by the following formula:
[0566] [Formula 53]
[0567]
[0568] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0569] [70-1] The treatment method according to [53-1], wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
[0570] [71-1] The method of [70-1], wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8.
[0571] [72-1] The treatment method according to [71-1], wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0572] [73-1] The method of any one of [70-1] to [72-1], wherein the antibody-drug conjugate is represented by the following formula:
[0573] [Formula 54]
[0574]
[0575] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0576] [74-1] The treatment method according to [53-1], wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[0577] [75-1] The method of [74-1], wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10.
[0578] [76-1] The treatment method according to [75-1], wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0579] [77-1] The method of any one of [74-1] to [76-1], wherein the antibody-drug conjugate is represented by the following formula:
[0580] [Formula 55]
[0581]
[0582] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0583] [78-1] The treatment method according to [53-1], wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[0584] [79-1] The method of [78-1], wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; and the light chain is composed of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12.
[0585] [80-1] The treatment method according to [79-1], wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0586] [81-1] The method of any one of [78-1] to [80-1], wherein the antibody-drug conjugate is represented by the following formula:
[0587] [Formula 56]
[0588]
[0589] wherein “antibody” indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0590] [82-1] The method according to [53-1], wherein the antibody in the antibody-drug conjugate is an anti-MUC1 antibody.
[0591] [83-1] The method according to [82-1], wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0592] [84-1] The method according to [83-1], wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0593] [85-1] The method according to [82-1], wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0594] [86-1] The method according to [85-1], wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0595] [87-1] The method according to any one of [82-1] to [86-1], wherein the antibody-drug conjugate is represented by the following formula:
[0596] [Formula 57]
[0597]
[0598] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0599] [D1] The method according to [53-1], wherein the antibody in the antibody-drug conjugate is an anti-CD37 antibody.
[0600] [D2] The method according to [D1], wherein the anti-CD37 antibody is an antibody selected from the following:
[0601] (a) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 16; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19,
[0602] (b) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 17; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19, and
[0603] (c) An antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO:18; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO:19.
[0604] [D3] The method according to [D1], wherein the anti-CD37 antibody is an antibody selected from the following:
[0605] (d) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 16; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19,
[0606] (e) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 17; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19, and
[0607] (f) An antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0608] [D4] The method according to [D1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:16; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0609] [D5] The method according to [D4], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0610] [D6] The method according to [D4] or [D5], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0611] [D7] The method according to [D1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:17; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0612] [D8] The method according to [D7], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0613] [D9] The method according to [D7] or [D8], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0614] [D10] The method according to [D1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0615] [D11] The method according to [D10], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0616] [D12] The method according to [D10] or [D11], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0617] [D13] The method according to any one of [D1] to [D12], wherein the antibody-drug conjugate is represented by the following formula:
[0618] [Formula 58]
[0619]
[0620] wherein “antibody” indicates an anti-CD37 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0621] [88-1] The treatment method according to any one of [52-1] to [59-1], wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
[0622] [89-1] The treatment method according to any one of [52-1] to [53-1] and [64-1] to [69-1], wherein the antibody-drug conjugate is dedabrafenib (DS-1062).
[0623] [90-1] The method according to any one of [52-1] to [89-1], [C1] to [C2], and [D1] to [D13], wherein the inhibitor is an EZH2 inhibitor.
[0624] [91-1] The method according to [90-1], wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
[0625] [92-1] The method according to any one of [52-1] to [89-1], [C1] to [C2] and [D1] to [D13], wherein the inhibitor is an EZH1 / 2 dual inhibitor.
[0626] [93-1] The method according to [92-1], wherein the inhibitor is vametadostat or a pharmaceutically acceptable salt thereof.
[0627] [94-1] The method according to [92-1] or [93-1], wherein the inhibitor is valmetostostat tosylate.
[0628] [95-1] The method according to any one of [52-1] to [94-1], [C1] to [C2] and [D1] to [D13], wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously or at different times.
[0629] [96-1] A method according to any one of [52-1] to [95-1], [C1] to [C2], [D1] to [D13] and [258-1], wherein the treatment method is used to treat at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma.
[0630] [97-1] The method according to [96-1], wherein the treatment method is used to treat breast cancer.
[0631] [98-1] The method according to [97-1], wherein the treatment method is used to treat triple-negative breast cancer.
[0632] [99-1] The method according to [96-1], wherein the treatment method is used to treat gastric cancer.
[0633] [100-1] The method according to [96-1], wherein the treatment method is used to treat ovarian cancer.
[0634] [101-1] The method according to [96-1], wherein the treatment method is used to treat lung cancer.
[0635] [102-1] The method according to [96-1], wherein the treatment method is used to treat pancreatic cancer.
[0636] [103-1] An antibody-drug conjugate for use in a method for treating a disease, wherein the method comprises administering the antibody-drug conjugate in combination with an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor, and an EZH1 / 2 dual inhibitor, wherein the antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker represented by the following formula in the antibody-drug conjugate:
[0637] [Formula 59]
[0638]
[0639] Where A represents the connection position with the antibody,
[0640] Conjugation to the antibody is via a thioether bond.
[0641] [104-1] An antibody-drug conjugate for the use according to [103-1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody, an anti-MUC1 antibody or an anti-CD37 antibody.
[0642] [105-1] An antibody-drug conjugate for the use according to [104-1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0643] [106-1] An antibody-drug conjugate for the use according to [105-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:2.
[0644] [107-1] An antibody-drug conjugate for the use according to [105-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO:1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2.
[0645] [108-1] An antibody-drug conjugate for the use according to [105-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:1, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:2.
[0646] [109-1] An antibody-drug conjugate for the use according to [105-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1; and the light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:2.
[0647] [110-1] The antibody-drug conjugate for use according to any one of [105-1] to [109-1], wherein the antibody-drug conjugate is represented by the following formula:
[0648] [Formula 60]
[0649]
[0650] wherein “antibody” indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0651] [111-1] An antibody-drug conjugate for the use according to [104-1], wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
[0652] [E1] An antibody-drug conjugate for the use according to [111-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 35 of SEQ ID NO:3, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 50 to 65 of SEQ ID NO:3, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 98 to 106 of SEQ ID NO:3; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 24 to 39 of SEQ ID NO:4, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 56 to 62 of SEQ ID NO:4, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 95 to 103 of SEQ ID NO:4.
[0653] [E2] An antibody-drug conjugate for the use according to [111-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 117 of SEQ ID NO:3; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO:4.
[0654] [112-1] An antibody-drug conjugate for the use according to [111-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:3, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:4.
[0655] [113-1] An antibody-drug conjugate for the use according to [112-1], wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0656] [114-1] An antibody-drug conjugate for use according to any one of [111-1] to [113-1] or [E1] to [E2], wherein the antibody-drug conjugate is represented by the following formula:
[0657] [Formula 61]
[0658]
[0659] wherein “antibody” indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0660] [115-1] An antibody-drug conjugate for the use according to [104-1], wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
[0661] [116-1] An antibody-drug conjugate for the use according to [115-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6.
[0662] [117-1] An antibody-drug conjugate for the use according to [115-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6.
[0663] [118-1] An antibody-drug conjugate for the use according to [115-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6.
[0664] [119-1] The antibody-drug conjugate for the use according to [118-1], wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0665] [120-1] An antibody-drug conjugate for use according to any one of [115-1] to [119-1], wherein the antibody-drug conjugate is represented by the following formula:
[0666] [Formula 62]
[0667]
[0668] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0669] [121-1] An antibody-drug conjugate for the use according to [104-1], wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
[0670] [122-1] An antibody-drug conjugate for the use according to [121-1], wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8.
[0671] [123-1] An antibody-drug conjugate for the use according to [122-1], wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0672] [124-1] An antibody-drug conjugate for use according to any one of [121-1] to [123-1], wherein the antibody-drug conjugate is represented by the following formula:
[0673] [Formula 63]
[0674]
[0675] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0676] [125-1] The antibody-drug conjugate for the use according to [104-1], wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[0677] [126-1] An antibody-drug conjugate for the use according to [125-1], wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10.
[0678] [127-1] The antibody-drug conjugate for use according to [126-1], wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0679] [128-1] The antibody-drug conjugate for use according to any one of [125-1] to [127-1], wherein the antibody-drug conjugate is represented by the following formula:
[0680] [Formula 64]
[0681]
[0682] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0683] [129-1] An antibody-drug conjugate for the use according to [104-1], wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[0684] [130-1] An antibody-drug conjugate for the use according to [129-1], wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12.
[0685] [131-1] The antibody-drug conjugate for the use according to [130-1], wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0686] [132-1] The antibody-drug conjugate for use according to any one of [129-1] to [131-1], wherein the antibody-drug conjugate is represented by the following formula:
[0687] [Formula 65]
[0688]
[0689] wherein “antibody” indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0690] [133-1] An antibody-drug conjugate for the use according to [104-1], wherein the antibody in the antibody-drug conjugate is an anti-MUC1 antibody.
[0691] [134-1] An antibody-drug conjugate for the use according to [133-1], wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0692] [135-1] The antibody-drug conjugate for use according to [134-1], wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0693] [136-1] An antibody-drug conjugate for the use according to [133-1], wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0694] [137-1] The antibody-drug conjugate for use according to [136-1], wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0695] [138-1] The antibody-drug conjugate for use according to any one of [133-1] to [137-1], wherein the antibody-drug conjugate is represented by the following formula:
[0696] [Formula 66]
[0697]
[0698] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0699] [F1] The antibody-drug conjugate for the use according to [104-1], wherein the antibody in the antibody-drug conjugate is an anti-CD37 antibody.
[0700] [F2] An antibody-drug conjugate for use according to [F1], wherein the anti-CD37 antibody is an antibody selected from the following:
[0701] (a) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 16; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19,
[0702] (b) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 17; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19, and
[0703] (c) An antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO:18; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO:19.
[0704] [F3] The antibody-drug conjugate for use according to [F1], wherein the anti-CD37 antibody is an antibody selected from the following:
[0705] (d) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 16; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19,
[0706] (e) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 17; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19, and
[0707] (f) An antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0708] [F4] An antibody-drug conjugate for the use according to [F1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:16; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0709] [F5] The antibody-drug conjugate for use according to [F4], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0710] [F6] The antibody-drug conjugate for use according to [F4] or [F5], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0711] [F7] An antibody-drug conjugate for the use according to [F1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:17; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0712] [F8] The antibody-drug conjugate for use according to [F7], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0713] [F9] The antibody-drug conjugate for use according to [F7] or [F8], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0714] [F10] An antibody-drug conjugate for the use according to [F1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0715] [F11] The antibody-drug conjugate for use according to [F10], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0716] [F12] The antibody-drug conjugate for use according to [F10] or [F11], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0717] [F13] An antibody-drug conjugate for use according to any one of [F1] to [F12], wherein the antibody-drug conjugate is represented by the following formula:
[0718] [Formula 67]
[0719]
[0720] wherein “antibody” indicates an anti-CD37 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0721] [139-1] An antibody-drug conjugate for use according to any one of [103-1] to [110-1], wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
[0722] [140-1] An antibody-drug conjugate for use according to any one of [103-1] to [104-1] and [115-1] to [120-1], wherein the antibody-drug conjugate is dedabrafenib (DS-1062).
[0723] [141-1] An antibody-drug conjugate for use according to any one of [103-1] to [140-1], [E1] to [E2] and [F1] to [F13], wherein the inhibitor is an EZH2 inhibitor.
[0724] [142-1] The antibody-drug conjugate for the use according to [141-1], wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
[0725] [143-1] An antibody-drug conjugate for use according to any one of [103-1] to [140-1], [E1] to [E2] and [F1] to [F13], wherein the inhibitor is an EZH1 / 2 dual inhibitor.
[0726] [144-1] The antibody-drug conjugate for the use according to [143-1], wherein the inhibitor is vametadostat or a pharmaceutically acceptable salt thereof.
[0727] [145-1] An antibody-drug conjugate for use according to [143-1] or [144-1], wherein the inhibitor is valmetostostat tosylate.
[0728] [146-1] An antibody-drug conjugate for use according to any one of [103-1] to [145-1], [E1] to [E2], and [F1] to [F13], wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously or at different times.
[0729] [147-1] An antibody-drug conjugate for use according to any one of [103-1] to [146-1], [E1] to [E2], [F1] to [F13] and [259-1], wherein the disease is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma.
[0730] [148-1] The antibody-drug conjugate for the use according to [147-1], wherein the disease is breast cancer.
[0731] [149-1] An antibody-drug conjugate for the use according to [148-1], wherein the disease is triple-negative breast cancer.
[0732] [150-1] The antibody-drug conjugate for the use according to [147-1], wherein the disease is gastric cancer.
[0733] [151-1] The antibody-drug conjugate for the use according to [147-1], wherein the disease is ovarian cancer.
[0734] [152-1] The antibody-drug conjugate for the use according to [147-1], wherein the disease is lung cancer.
[0735] [153-1] The antibody-drug conjugate for the use according to [147-1], wherein the disease is pancreatic cancer.
[0736] [154-1] Use of an antibody-drug conjugate or an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor for preparing a medicament for treating a disease by administering the antibody-drug conjugate and the inhibitor in combination, wherein the antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker represented by the following formula in the antibody-drug conjugate:
[0737] [Formula 68]
[0738]
[0739] Where A represents the connection position with the antibody,
[0740] Conjugation to the antibody is via a thioether bond.
[0741] [155-1] The use according to [154-1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody, an anti-MUC1 antibody or an anti-CD37 antibody.
[0742] [156-1] The use according to [155-1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0743] [157-1] According to the use of [156-1], the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:2.
[0744] [158-1] The use according to [156-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO:1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2.
[0745] [159-1] The use according to [156-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of the amino acid sequence shown in SEQ ID NO:1, and the light chain is composed of the amino acid sequence shown in SEQ ID NO:2.
[0746] [160-1] The use according to [156-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1; and the light chain is composed of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:2.
[0747] [161-1] The use according to any one of [156-1] to [160-1],
[0748] The antibody-drug conjugate is represented by the following formula:
[0749] [Formula 69]
[0750]
[0751] wherein “antibody” indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0752] [162-1] The use according to [155-1], wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
[0753] [G1] The use according to [162-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 35 of SEQ ID NO:3, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 50 to 65 of SEQ ID NO:3, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 98 to 106 of SEQ ID NO:3; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 24 to 39 of SEQ ID NO:4, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 56 to 62 of SEQ ID NO:4, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 95 to 103 of SEQ ID NO:4.
[0754] [G2] The use according to [162-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 117 of SEQ ID NO:3; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO:4.
[0755] [163-1] The use according to [162-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of the amino acid sequence shown in SEQ ID NO:3, and the light chain is composed of the amino acid sequence shown in SEQ ID NO:4.
[0756] [164-1] The use according to [163-1], wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0757] [165-1] The use according to any one of [162-1] to [164-1] and [G1] to [G2], wherein the antibody-drug conjugate is represented by the following formula:
[0758] [Formula 70]
[0759]
[0760] wherein “antibody” indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0761] [166-1] The use according to [155-1], wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
[0762] [167-1] According to the use of [166-1], the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6.
[0763] [168-1] The use according to [166-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6.
[0764] [169-1] The use according to [166-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain is composed of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6.
[0765] [170-1] The use according to [169-1], wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0766] [171-1] The use according to any one of [166-1] to [170-1], wherein the antibody-drug conjugate is represented by the following formula:
[0767] [Formula 71]
[0768]
[0769] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0770] [172-1] The use according to [155-1], wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
[0771] [173-1] The use according to [172-1], wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8.
[0772] [174-1] The use according to [173-1], wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0773] [175-1] The use according to any one of [172-1] to [174-1], wherein the antibody-drug conjugate is represented by the following formula:
[0774] [Formula 72]
[0775]
[0776] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0777] [176-1] The use according to [155-1], wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[0778] [177-1] The use according to [176-1], wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10.
[0779] [178-1] The use according to [177-1], wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0780] [179-1] The use according to any one of [176-1] to [178-1], wherein the antibody-drug conjugate is represented by the following formula:
[0781] [Formula 73]
[0782]
[0783] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0784] [180-1] The use according to [155-1], wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[0785] [181-1] According to the use of [180-1], the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain is composed of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; the light chain is composed of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12.
[0786] [182-1] The use according to [181-1], wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0787] [183-1] The use according to any one of [180-1] to [182-1], wherein the antibody-drug conjugate is represented by the following formula:
[0788] [Formula 74]
[0789]
[0790] wherein “antibody” indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0791] [184-1] The use according to [155-1], wherein the antibody in the antibody-drug conjugate is an anti-MUC1 antibody.
[0792] [185-1] The use according to [184-1], wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0793] [186-1] The use according to [185-1], wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0794] [187-1] The use according to [184-1], wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0795] [188-1] The use according to [187-1], wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0796] [189-1] The use according to any one of [184-1] to [188-1], wherein the antibody-drug conjugate is represented by the following formula:
[0797] [Formula 75]
[0798]
[0799] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0800] [H1] The use according to [155-1], wherein the antibody in the antibody-drug conjugate is an anti-CD37 antibody.
[0801] [H2] The use according to [H1], wherein the anti-CD37 antibody is an antibody selected from the following:
[0802] (a) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 16; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19,
[0803] (b) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 17; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19, and
[0804] (c) An antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO:18; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO:19.
[0805] [H3] The use according to [H1], wherein the anti-CD37 antibody is an antibody selected from the following:
[0806] (d) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 16; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19,
[0807] (e) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 17; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19, and
[0808] (f) An antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0809] [H4] The use according to [H1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:16; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0810] [H5] The use according to [H4], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0811] [H6] The use according to [H4] or [H5], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0812] [H7] The use according to [H1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:17; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0813] [H8] The use according to [H7], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0814] [H9] The use according to [H7] or [H8], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0815] [H10] The use according to [H1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0816] [H11] The use according to [H10], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0817] [H12] The use according to [H10] or [H11], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0818] [H13] The use according to any one of [H1] to [H12], wherein the antibody-drug conjugate is represented by the following formula:
[0819] [Formula 76]
[0820]
[0821] wherein “antibody” indicates an anti-CD37 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0822] [190-1] The use according to any one of [154-1] to [161-1], wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
[0823] [191-1] The use according to any one of [154-1] to [155-1] and [166-1] to [171-1], wherein the antibody-drug conjugate is dedabrafenib (DS-1062).
[0824] [192-1] The use according to any one of [154-1] to [191-1], [G1] to [G2] and [H1] to [H13], wherein the inhibitor is an EZH2 inhibitor.
[0825] [193-1] The use according to [192-1], wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
[0826] [194-1] The use according to any one of [154-1] to [191-1], [G1] to [G2] and [H1] to [H13], wherein the inhibitor is an EZH1 / 2 dual inhibitor.
[0827] [195-1] The use according to [194-1], wherein the inhibitor is vametadostat or a pharmaceutically acceptable salt thereof.
[0828] [196-1] The use according to [194-1] or [195-1], wherein the inhibitor is valmetostostat tosylate.
[0829] [197-1] The use according to any one of [154-1] to [196-1], [G1] to [G2] and [H1] to [H13], wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously or at different times.
[0830] [198-1] The use according to any one of [154-1] to [197-1], [G1] to [G2], [H1] to [H13] and [260-1], wherein the disease is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma.
[0831] [199-1] The use according to [198-1], wherein the disease is breast cancer.
[0832] [200-1] The use according to [199-1], wherein the disease is triple-negative breast cancer.
[0833] [201-1] The use according to [198-1], wherein the disease is gastric cancer.
[0834] [202-1] The use according to [198-1], wherein the disease is ovarian cancer.
[0835] [203-1] The use according to [198-1], wherein the disease is lung cancer.
[0836] [204-1] The use according to [198-1], wherein the disease is pancreatic cancer.
[0837] [205-1] An inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor for use in a method for treating a disease, wherein the method comprises administering the inhibitor in combination with an antibody-drug conjugate, wherein the antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker in the antibody-drug conjugate is represented by the following formula:
[0838] [Formula 77]
[0839]
[0840] Where A represents the connection position with the antibody,
[0841] Conjugation to the antibody is via a thioether bond.
[0842] [206-1] An inhibitor for the use according to [205-1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody, an anti-MUC1 antibody or an anti-CD37 antibody.
[0843] [207-1] The inhibitor for use according to [206-1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0844] [208-1] An inhibitor for the use according to [207-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:2.
[0845] [209-1] An inhibitor for the use according to [207-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO:1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2.
[0846] [210-1] An inhibitor for the use according to [207-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consists of the amino acid sequence shown in SEQ ID NO:1, and the light chain consists of the amino acid sequence shown in SEQ ID NO:2.
[0847] [211-1] An inhibitor for the use according to [207-1], wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1; and the light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:2.
[0848] [212-1] The inhibitor for use according to any one of [207-1] to [211-1], wherein the antibody-drug conjugate is represented by the following formula:
[0849] [Formula 78]
[0850]
[0851] wherein “antibody” indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0852] [213-1] The inhibitor for use according to [206-1], wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
[0853] [I1] An inhibitor for the use according to [213-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 35 of SEQ ID NO:3, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 50 to 65 of SEQ ID NO:3, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 98 to 106 of SEQ ID NO:3; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 24 to 39 of SEQ ID NO:4, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 56 to 62 of SEQ ID NO:4, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 95 to 103 of SEQ ID NO:4.
[0854] [I2] An inhibitor for the use according to [213-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 117 of SEQ ID NO:3; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO:4.
[0855] [214-1] An inhibitor for the use according to [213-1], wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consists of the amino acid sequence shown in SEQ ID NO:3, and the light chain consists of the amino acid sequence shown in SEQ ID NO:4.
[0856] [215-1] An inhibitor for use according to [214-1], wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0857] [216-1] The inhibitor for use according to any one of [213-1] to [215-1] and [I1] to [I2], wherein the antibody-drug conjugate is represented by the following formula:
[0858] [Formula 79]
[0859]
[0860] wherein “antibody” indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0861] [217-1] The inhibitor for use according to [206-1], wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
[0862] [218-1] An inhibitor for the use according to [217-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6.
[0863] [219-1] An inhibitor for the use according to [217-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6.
[0864] [220-1] An inhibitor for the use according to [217-1], wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6.
[0865] [221-1] The inhibitor for use according to [220-1], wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0866] [222-1] The inhibitor for use according to any one of [217-1] to [221-1], wherein the antibody-drug conjugate is represented by the following formula:
[0867] [Formula 80]
[0868]
[0869] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0870] [223-1] The inhibitor for use according to [206-1], wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
[0871] [224-1] An inhibitor for the use according to [223-1], wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8.
[0872] [225-1] An inhibitor for use according to [224-1], wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0873] [226-1] The inhibitor for use according to any one of [223-1] to [225-1], wherein the antibody-drug conjugate is represented by the following formula:
[0874] [Formula 81]
[0875]
[0876] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.5.
[0877] [227-1] The inhibitor for use according to [206-1], wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[0878] [228-1] An inhibitor for the use according to [227-1], wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10.
[0879] [229-1] The inhibitor for use according to [228-1], wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0880] [230-1] The inhibitor for use according to any one of [227-1] to [229-1], wherein the antibody-drug conjugate is represented by the following formula:
[0881] [Formula 82]
[0882]
[0883] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0884] [231-1] The inhibitor for use according to [206-1], wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[0885] [232-1] An inhibitor for the use according to [231-1], wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12.
[0886] [233-1] The inhibitor for use according to [232-1], wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0887] [234-1] The inhibitor for use according to any one of [231-1] to [233-1], wherein the anti-CDH6 antibody-drug conjugate is represented by the following formula:
[0888] [Formula 83]
[0889]
[0890] wherein “antibody” indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0891] [235-1] The inhibitor for use according to [206-1], wherein the antibody in the antibody-drug conjugate is an anti-MUC1 antibody.
[0892] [236-1] An inhibitor for the use according to [235-1], wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0893] [237-1] The inhibitor for use according to [236-1], wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0894] [238-1] An inhibitor for the use according to [235-1], wherein the anti-MUC1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:15.
[0895] [239-1] The inhibitor for use according to [238-1], wherein the anti-MUC1 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
[0896] [240-1] The inhibitor for use according to any one of [235-1] to [239-1], wherein the antibody-drug conjugate is represented by the following formula:
[0897] [Formula 84]
[0898]
[0899] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
[0900] [J1] The inhibitor for use according to [206-1], wherein the antibody in the antibody-drug conjugate is an anti-CD37 antibody.
[0901] [J2] The inhibitor for use according to [J1], wherein the anti-CD37 antibody is an antibody selected from the following:
[0902] (a) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 16; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19,
[0903] (b) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 17; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19, and
[0904] (c) An antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO:18; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO:19.
[0905] [J3] The inhibitor for use according to [J1], wherein the anti-CD37 antibody is an antibody selected from the following:
[0906] (d) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 16; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19,
[0907] (e) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 17; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19, and
[0908] (f) An antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0909] [J4] An inhibitor for the use according to [J1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:16; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0910] [J5] The inhibitor for use according to [J4], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0911] [J6] The inhibitor for use according to [J4] or [J5], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0912] [J7] An inhibitor for the use according to [J1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:17; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0913] [J8] The inhibitor for use according to [J7], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0914] [J9] The inhibitor for use according to [J7] or [J8], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0915] [J10] An inhibitor for the use according to [J1], wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[0916] [J11] The inhibitor for use according to [J10], wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
[0917] [J12] The inhibitor for use according to [J10] or [J11], wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
[0918] [J13] An inhibitor for use according to any one of [J1] to [J12], wherein the antibody-drug conjugate is represented by the following formula:
[0919] [Formula 85]
[0920]
[0921] wherein “antibody” indicates an anti-CD37 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
[0922] [241-1] An inhibitor for use according to any one of [205-1] to [212-1], wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
[0923] [242-1] An inhibitor for use according to any one of [205-1] to [206-1] and [217-1] to [222-1], wherein the antibody-drug conjugate is dedabrafenib (DS-1062).
[0924] [243-1] An inhibitor for use according to any one of [205-1] to [242-1], [I1] to [I2], and [J1] to [J13], wherein the inhibitor is an EZH2 inhibitor.
[0925] [244-1] The inhibitor for the use according to [243-1], wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
[0926] [245-1] An inhibitor for use according to any one of [205-1] to [242-1], [I1] to [I2] and [J1] to [J13], wherein the inhibitor is an EZH1 / 2 dual inhibitor.
[0927] [246-1] The inhibitor for the use according to [245-1], wherein the inhibitor is vametosat or a pharmaceutically acceptable salt thereof.
[0928] [247-1] An inhibitor for use according to [245-1] or [246-1], wherein the inhibitor is valmetostostat tosylate.
[0929] [248-1] An inhibitor for use according to any one of [205-1] to [247-1], [I1] to [I2] and [J1] to [J13], wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously or at different times.
[0930] [249-1] An inhibitor for use according to any one of [205-1] to [248-1], [I1] to [I2], [J1] to [J13] and [261-1], wherein the disease is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma.
[0931] [250-1] An inhibitor for use according to [249-1], wherein the disease is breast cancer.
[0932] [251-1] An inhibitor for use according to [250-1], wherein the disease is triple-negative breast cancer.
[0933] [252-1] An inhibitor for the use according to [249-1], wherein the disease is gastric cancer.
[0934] [253-1] An inhibitor for the use according to [249-1], wherein the disease is ovarian cancer.
[0935] [254-1] An inhibitor for use according to [249-1], wherein the disease is lung cancer.
[0936] [255-1] An inhibitor for the use according to [249-1], wherein the disease is pancreatic cancer.
[0937] [256-1] The pharmaceutical product according to any one of [1-1] to [51-1], [A1] to [A2], [B1] to [B13] and [257-1], wherein the pharmaceutical product is a pharmaceutical composition.
[0938] [257-1] The pharmaceutical product according to any one of [1-1] to [44-1], [A1] to [A2] and [B1] to [B13], wherein the pharmaceutical product is for treating cancer.
[0939] [258-1] The treatment method according to any one of [52-1] to [95-1], [C1] to [C2] and [D1] to [D13], wherein the treatment method is used to treat cancer.
[0940] [259-1] An antibody-drug conjugate for use according to any one of [103-1] to [146-1], [E1] to [E2], and [F1] to [F13], wherein the disease is cancer.
[0941] [260-1] The use according to any one of [154-1] to [197-1], [G1] to [G2] and [H1] to [H13], wherein the disease is cancer.
[0942] [261-1] An inhibitor for use according to any one of [205-1] to [248-1], [I1] to [I2], and [J1] to [J13], wherein the disease is cancer.
[0943] Advantageous Effects of the Invention
[0944] The present invention provides a pharmaceutical product, wherein a specific antibody-drug conjugate is administered in combination with an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor, and / or a therapeutic method, wherein the specific antibody-drug conjugate and the inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor are administered to a subject in combination. BRIEF DESCRIPTION OF THE DRAWINGS
[0946] [ Figure 1 ] Figure 1 The amino acid sequence of the heavy chain of the anti-HER2 antibody is shown (SEQ ID NO: 1).
[0947] [ Figure 2 ] Figure 2 The amino acid sequence of the light chain of the anti-HER2 antibody is shown (SEQ ID NO: 2).
[0948] [ Figure 3 ] Figure 3 The amino acid sequence of the heavy chain of the anti-HER3 antibody is shown (SEQ ID NO: 3).
[0949] [ Figure 4 ] Figure 4 The amino acid sequence of the light chain of the anti-HER3 antibody is shown (SEQ ID NO: 4).
[0950] [ Figure 5 ] Figure 5 The amino acid sequence of the heavy chain of the anti-TROP2 antibody is shown (SEQ ID NO: 5).
[0951] [ Figure 6 ] Figure 6 The amino acid sequence of the light chain of the anti-TROP2 antibody is shown (SEQ ID NO: 6).
[0952] [ Figure 7 ] Figure 7 The amino acid sequence of the heavy chain of the anti-B7-H3 antibody is shown (SEQ ID NO: 7).
[0953] [ Figure 8 ] Figure 8 The amino acid sequence of the light chain of the anti-B7-H3 antibody is shown (SEQ ID NO: 8).
[0954] [ Fig. 9 ] Fig. 9 The amino acid sequence of the heavy chain of the anti-GPR20 antibody is shown (SEQ ID NO: 9).
[0955] [ Fig.10 ] Fig.10 The amino acid sequence of the light chain of the anti-GPR20 antibody is shown (SEQ ID NO: 10).
[0956] [ Fig.11 ] Fig.11 The amino acid sequence of the heavy chain of the anti-CDH6 antibody is shown (SEQ ID NO: 11).
[0957] [ Fig.12 ] Fig.12 The amino acid sequence of the light chain of the anti-CDH6 antibody is shown (SEQ ID NO: 12).
[0958] [ Fig.13 ] Fig.13 The amino acid sequence of the heavy chain of the anti-MUC1 antibody (PMN54Q) is shown (SEQ ID No: 13).
[0959] [ Fig.14 ] Fig.14 The amino acid sequence of the heavy chain of the anti-MUC1 antibody (PankoMab) is shown (SEQ ID No: 14).
[0960] [ Fig.15 ] Fig.15 The amino acid sequence of the light chain of the anti-MUCl antibodies (PM N54Q and PankoMab) is shown (SEQ ID No: 15).
[0961] [ Fig.16 ] Fig.16 The graph shows the tumor growth inhibitory effect in mice with subcutaneously transplanted NCI-N87 cells in each of the HER2-ADC (1) and Compound A single administration groups and the HER2-ADC (1) and Compound A combination administration groups.
[0962] [ Fig.17 ] Fig.17The graph shows the tumor growth inhibitory effect in mice with subcutaneously transplanted JIMT-1 cells in each of the HER2-ADC (1) and compound A single administration groups and the HER2-ADC (1) and compound A combination administration groups.
[0963] [ Fig.18 ] Fig.18 The graph shows the tumor growth inhibitory effect in mice with subcutaneously transplanted MDA-MB-453 cells in each of the HER2-ADC (1) and Compound A single administration groups and the HER2-ADC (1) and Compound A combination administration groups.
[0964] [ Fig.19 ] Fig.19 The graph shows the tumor growth inhibitory effect in mice with subcutaneously transplanted MX-1 cells in each of the HER2-ADC (1) and compound A single administration groups and the HER2-ADC (1) and compound A combination administration groups.
[0965] [ Fig. 20 ] Fig. 20 The amino acid sequence of the heavy chain of the anti-CD37 antibody (hmAb-H541) is shown (SEQ ID No: 16).
[0966] [ Fig.21 ] Fig.21 The amino acid sequence of the heavy chain of the anti-CD37 antibody (hmAb-H551) is shown (SEQ ID No: 17).
[0967] [ Fig. 22 ] Fig. 22 The amino acid sequence of the heavy chain of the anti-CD37 antibody (hmAb-H11a) is shown (SEQ ID No: 18).
[0968] [ Fig.23 ] Fig.23 The amino acid sequence of the light chain of the anti-CD37 antibody (hmAb-L11) is shown (SEQ ID No: 19).
[0969] [ Fig.24 ] Fig.24 The graph shows the tumor growth inhibitory effect in mice with subcutaneously transplanted ZR-75-1 cells in each of the HER2-ADC (1) and Compound A single administration groups and the HER2-ADC (1) and Compound A combination administration groups.
[0970] [ Fig.25 ] Fig.25The graph shows the tumor growth inhibitory effect in mice with subcutaneously transplanted Calu-3 cells in each of the HER2-ADC (1) and Compound A single administration groups and the HER2-ADC (1) and Compound A combination administration groups.
[0971] [ Fig.26 ] Fig.26 The graph shows the tumor growth inhibitory effect in mice with subcutaneously transplanted NCI-H358 cells in each of the TROP2-ADC (1) and Compound A single administration groups and the TROP2-ADC (1) and Compound A combination administration groups.
[0972] [ Fig. 27 ] Fig. 27 The graph shows the tumor growth inhibitory effect in mice with subcutaneously transplanted JIMT-1 cells in each of the HER3-ADC (1) and compound A single administration groups and the HER3-ADC (1) and compound A combination administration groups.
[0973] [ Fig.28 ] Fig.28 The graph shows the tumor growth inhibitory effect in mice with subcutaneously transplanted WSU-DLCL2 cells in each of the CD37-ADC (1) and Compound A single administration groups and the CD37-ADC (1) and Compound A combination administration groups.
[0974] [ Fig.29 ] Fig.29 The graph shows the tumor growth inhibitory effect in mice with subcutaneously transplanted NCI-H660 cells in each of the B7-H3-ADC (1) and Compound A single administration groups and the B7-H3-ADC (1) and Compound A combination administration groups.
[0975] [ Fig.30 ] Fig.30 The amino acid sequence of CDRH1 of the heavy chain of the anti-HER2 antibody is shown.
[0976] [ Fig.31 ] Fig.31 The amino acid sequence of CDRH2 of the heavy chain of the anti-HER2 antibody is shown.
[0977] [ Fig.32 ] Fig.32 The amino acid sequence of CDRH3 of the heavy chain of the anti-HER2 antibody is shown.
[0978] [ Fig.33 ] Fig.33 The amino acid sequence of CDRL1 of the light chain of the anti-HER2 antibody is shown.
[0979] [ Fig.34 ] Fig.34 The amino acid sequence of CDRL2 of the light chain of the anti-HER2 antibody is shown.
[0980] [ Fig.35 ] Fig.35 The amino acid sequence of CDRL3 of the light chain of the anti-HER2 antibody is shown.
[0981] [ Fig.36 ] Fig.36 The amino acid sequences of the heavy chain variable regions of the anti-HER2 antibodies are shown.
[0982] [ Fig.37 ] Fig.37 The amino acid sequences of the light chain variable regions of the anti-HER2 antibodies are shown.
[0983] [ Fig.38 ] Fig.38 The amino acid sequence of CDRH1 of the heavy chain of the anti-TROP2 antibody is shown.
[0984] [ Fig.39 ] Fig.39 The amino acid sequence of CDRH2 of the heavy chain of the anti-TROP2 antibody is shown.
[0985] [ Fig.40 ] Fig.40 The amino acid sequence of CDRH3 of the heavy chain of the anti-TROP2 antibody is shown.
[0986] [ Fig.41 ] Fig.41 The amino acid sequence of CDRL1 of the light chain of the anti-TROP2 antibody is shown.
[0987] [ Fig.42 ] Fig.42 The amino acid sequence of CDRL2 of the light chain of the anti-TROP2 antibody is shown.
[0988] [ Fig.43 ] Fig.43 The amino acid sequence of CDRL3 of the light chain of the anti-TROP2 antibody is shown.
[0989] [ Fig.44 ] Fig.44 The amino acid sequences of the heavy chain variable regions of the anti-TROP2 antibodies are shown.
[0990] [ Fig.45 ] Fig.45 The amino acid sequences of the light chain variable regions of the anti-TROP2 antibodies are shown.
[0991] Description of the implementation plan
[0992] Hereinafter, a preferred mode of carrying out the present invention is described. The embodiment described below is given merely as an example to illustrate a typical embodiment of the present invention and is not intended to limit the scope of the present invention.
[0993] 1. Antibody-drug conjugates
[0994] The antibody-drug conjugate used in the present invention is an antibody-drug conjugate in which the drug-linker is represented by the following formula:
[0995] [Formula 86]
[0996]
[0997] Where A represents the connection position with the antibody,
[0998] Conjugation to the antibody is via a thioether bond.
[0999] In the present invention, the partial structure consisting of a linker and a drug in the antibody-drug conjugate is referred to as a "drug-linker". The drug-linker is connected to a sulfhydryl group (i.e., a sulfur atom of a cysteine residue) formed at the interchain disulfide bond site (two sites between heavy chains, and two sites between heavy chains and light chains) in the antibody.
[1000] The drug-linker of the present invention includes exotecan (IUPAC name: (1S,9S)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione (also expressed as chemical name: (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione)) (which is a topoisomerase I inhibitor) as a component. Exotecan is a camptothecin derivative having an antitumor effect, which is represented by the following formula:
[1001] [Formula 87]
[1002]
[1003] The antibody-drug conjugate used in the present invention can also be represented by the following formula:
[1004] [Formula 88]
[1005]
[1006] wherein the drug-linker is conjugated to the antibody via a thioether bond. n has the same meaning as the so-called average number of conjugated drug molecules (DAR; drug / antibody ratio) and indicates the average number of drug-linker units conjugated per antibody molecule.
[1007] After migrating into cancer cells, the antibody-drug conjugate used in the present invention is cleaved at the linker portion to release a compound represented by the following formula:
[1008] [Formula 89]
[1009]
[1010] The aforementioned compound is presumed to be the original source of the antitumor activity of the antibody-drug conjugate used in the present invention, and has been confirmed to have a topoisomerase I inhibitory effect (Ogitani Y. et al., Clinical Cancer Research, 2016 Oct 15; 22(20):5097-5108, electronically published on Mar 29, 2016).
[1011] It is also known that the antibody-drug conjugate used in the present invention has a bystander effect (Ogitani Y. et al., Cancer Science (2016) 107, 1039-1046).
[1012] The bystander effect is achieved by a process such that the antibody-drug conjugate used in the present invention is internalized into cancer cells expressing the target, and the aforementioned compound is released and then also exerts an anti-tumor effect on cancer cells existing in the surroundings but not expressing the target.
[1013] When the antibody-drug conjugate according to the present invention is used in combination with an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor, and an EZH1 / 2 dual inhibitor, the bystander effect also exerts an excellent anti-tumor effect.
[1014] 2. Antibodies in Antibody-Drug Conjugates
[1015] The antibody in the antibody-drug conjugate used in the present invention can be derived from any species, and is preferably derived from human, rat, mouse or rabbit. In the case where the antibody is derived from a species other than human, it is preferably chimerized or humanized using well-known techniques. The antibody of the present invention can be a polyclonal antibody or a monoclonal antibody, preferably a monoclonal antibody.
[1016] The antibody in the antibody-drug conjugate used in the present invention is preferably an antibody having a feature of being able to target cancer cells, and is preferably an antibody having, for example, a property of being able to recognize cancer cells, a property of being able to bind to cancer cells, a property of being internalized into cancer cells, and / or a cytocidal activity against cancer cells.
[1017] Flow cytometry can be used to confirm the binding activity of antibodies to cancer cells. The internalization of antibodies into tumor cells can be confirmed using the following assays: (1) using a second antibody (fluorescently labeled) bound to a therapeutic antibody, visualizing the antibody incorporated into the cell under a fluorescence microscope (Cell Death and Differentiation (2008) 15, 751-761), (2) using a second antibody (fluorescently labeled) bound to a therapeutic antibody, measuring the fluorescence intensity of the incorporated cell (Molecular Biology of the Cell, Vol. 15, 5268-5282, December 2004), or (3) using a Mab-ZAP assay of an immunotoxin bound to a therapeutic antibody, wherein the toxin is released after incorporation into the cell to inhibit cell growth (Bio Techniques 28: 162-165, January 2000). As an immunotoxin, a recombinant composite protein of a diphtheria toxin catalytic domain and protein G can be used.
[1018] The anti-tumor activity of the antibody can be confirmed in vitro by measuring the inhibitory activity on cell growth. For example, a cancer cell line overexpressing the target protein of the antibody is cultured, and different concentrations of the antibody are added to the culture system to determine the inhibitory activity on lesion formation, colony formation, and sphere growth. The anti-tumor activity can be confirmed in vivo, for example, by administering the antibody to nude mice transplanted with a cancer cell line that highly expresses the target protein, and measuring the changes in the cancer cells.
[1019] Since the conjugated compound in the antibody-drug conjugate exerts an anti-tumor effect, it is preferred but not essential that the antibody itself should have an anti-tumor effect. In order to specifically and selectively exert the cytotoxic activity of the anti-tumor compound on cancer cells, it is important and also preferred that the antibody should have the property of being internalized to migrate into cancer cells.
[1020] The antibodies in the antibody-drug conjugates used in the present invention can be obtained by procedures known in the art. For example, the antibodies of the present invention can be obtained using methods commonly used in the art, including immunizing animals with antigenic polypeptides, and collecting and purifying antibodies produced in vivo. The origin of the antigen is not limited to humans, and animals can be immunized with antigens derived from non-human animals such as mice, rats, etc. In this case, the cross-reactivity of the antibody bound to the obtained heterologous antigen and the human antigen can be tested to screen antibodies applicable to human diseases.
[1021] Alternatively, antibody-producing cells that produce antibodies against an antigen can be fused with myeloma cells to establish hybridomas according to methods known in the art (e.g., Kohler and Milstein, Nature (1975) 256, pp. 495-497; Kennet, R., ed., Monoclonal Antibodies, pp. 365-367, Plenum Press, NY (1980)) and monoclonal antibodies can be obtained from the hybridomas.
[1022] Antigens can be obtained by genetically engineering host cells to produce genes encoding antigenic proteins. Specifically, a vector that allows the expression of the antigenic gene is prepared and transferred into a host cell so that the gene is expressed. The antigen expressed in this way can be purified. Antibodies can also be obtained by immunizing animals with the above-mentioned genetically engineered antigen-expressing cells or cell lines expressing the antigen.
[1023] The antibody in the antibody-drug conjugate used in the present invention is preferably a recombinant antibody (such as a chimeric antibody or a humanized antibody) obtained by artificial modification in order to reduce heterologous antigenicity to humans, or preferably an antibody having only a gene sequence of an antibody derived from humans, i.e., a human antibody. These antibodies can be produced using known methods.
[1024] As a chimeric antibody, there can be exemplified an antibody in which the antibody variable region and constant region are derived from different species, for example, a chimeric antibody in which a mouse- or rat-derived antibody variable region is linked to a human-derived antibody constant region (Proc. Natl. Acad. Sci. USA, 81, 6851-6855, (1984)).
[1025] Examples of humanized antibodies include antibodies obtained by incorporating only the complementarity determining region (CDR) of a heterologous antibody into a human-derived antibody (Nature (1986) 321, pp. 522-525), antibodies obtained by transplanting a portion of the amino acid residues of the framework of a heterologous antibody and the CDR sequence of a heterologous antibody into a human antibody by a CDR transplantation method (WO 90 / 07861), and antibodies humanized using a gene conversion mutagenesis strategy (U.S. Pat. No. 5,821,337).
[1026] As human antibodies, antibodies produced using human antibody-producing mice having human chromosome fragments (containing genes for heavy and light chains of human antibodies) can be exemplified (see Tomizuka, K. et al., Nature Genetics (1997) 16, pp. 133-143; Kuroiwa, Y. et al., Nucl. Acids Res. (1998) 26, pp. 3447-3448; Yoshida, H. et al., Animal Cell Technology: Basic and Applied Aspects vol. 10, pp. 69-73 (Kitagawa, Y., Matsuda, T. and Iijima, S. eds.), Kluwer Academic Publishers, 1999; Tomizuka, K. et al., Proc. Natl. Acad. Sci. USA (2000) 97, pp. 722-727, etc.). As an alternative, antibodies obtained by phage display, which are selected from human antibody libraries (see Wormstone, IM et al., Investigative Ophthalmology & Visual Science. (2002) 43 (7), pp. 2301-2308; Carmen, S. et al., Briefings in Functional Genomics and Proteomics (2002), 1 (2), pp. 189-203; Siriwardena, D. et al., Ophthalmology (2002) 109 (3), pp. 427-431, etc.) can be exemplified.
[1027] In the antibody in the antibody-drug conjugate used in the present invention, modified variants of the antibody are also included. The modified variant refers to a variant obtained by chemically or biologically modifying the antibody according to the present invention. Examples of chemically modified variants include: variants including the connection of a chemical part to an amino acid backbone, variants including the connection of a chemical part to an N-connected or O-connected carbohydrate chain, etc. Examples of biologically modified variants include: variants obtained by post-translational modification (such as N-connected or O-connected glycosylation, N- or C-terminal processing, deamidation, isomerization of aspartic acid or oxidation of methionine), and variants wherein a methionine residue is added to the N-terminus by expression in a prokaryotic host cell. In addition, antibodies labeled in order to be able to detect or separate antibodies or antigens according to the present invention, such as enzyme-labeled antibodies, fluorescently labeled antibodies, and affinity-labeled antibodies, are also included in the meaning of modified variants. Such modified variants of antibodies according to the present invention can be used to improve the stability and blood retention of antibodies, reduce their antigenicity, detect or separate antibodies or antigens, etc.
[1028] In addition, by adjusting the modification (glycosylation, defucosylation, etc.) of the polysaccharide connected with the antibody according to the present invention, the cytotoxic activity of the cell of antibody dependence can be enhanced. As the technology for adjusting the modification of antibody polysaccharide, known International Publication No. WO 99 / 54342, International Publication No. WO 00 / 61739, International Publication No. WO 02 / 31140, International Publication No. WO 2007 / 133855, International Publication No. WO 2013 / 120066, etc. But, described technology is not limited to this. In the antibody according to the present invention, also include the antibody wherein the modification of polysaccharide is regulated.
[1029] It is known that the lysine residue at the carboxyl terminus of the heavy chain of antibodies produced in cultured mammalian cells is deleted (Journal of Chromatography A, 705: 129-134 (1995)), and it is also known that two amino acid residues (glycine and lysine) at the carboxyl terminus of the heavy chain of antibodies produced in cultured mammalian cells are deleted and the proline residue newly located at the carboxyl terminus is amidated (Analytical Biochemistry, 360: 75-83 (2007)). However, such deletions and modifications of the heavy chain sequence do not affect the antigen binding affinity and effector function (complement activation, antibody-dependent cellular cytotoxicity, etc.) of the antibody. Therefore, in the antibodies according to the present invention, antibodies and functional fragments of the antibodies that have undergone such modifications are also included, and deletion variants in which one or two amino acids are deleted at the carboxyl terminus of the heavy chain, variants obtained by amidating the deletion variants (e.g., heavy chains in which the carboxyl terminal proline residue is amidated), etc. are also included. The type of deletion variant having a deletion at the carboxyl terminus of the heavy chain of the antibody according to the present invention is not limited to the above variants, as long as the antigen binding affinity and effector function are retained. The two heavy chains constituting the antibody according to the present invention may be a type selected from the full-length heavy chain and the above-mentioned deletion variants, or may be a combination of two types selected therefrom. The type and culture conditions of the cultured mammalian cells producing the antibody according to the present invention may affect the ratio of the amount of each deletion variant; however, an antibody in which one amino acid residue at the carboxyl terminus is deleted in both heavy chains of the antibody according to the present invention can be preferably exemplified.
[1030] The isotype of the antibody according to the present invention may be, for example, IgG (IgG1, IgG2, IgG3, IgG4), preferably IgG1 or IgG2.
[1031] Examples of antibodies in the antibody-drug conjugates used in the present invention may include, but are not particularly limited to, anti-HER2 antibodies, anti-HER3 antibodies, anti-TROP2 antibodies, anti-B7-H3 antibodies, anti-GPR20 antibodies, anti-CDH6 antibodies, anti-CD3 antibodies, anti-CD30 antibodies, anti-CD33 antibodies, anti-CD37 antibodies, anti-CD56 antibodies, anti-CD98 antibodies, anti-DR5 antibodies, anti-EGFR antibodies, anti-EPHA2 antibodies, anti-FGF Antibodies include anti-HER2, anti-HER3, anti-TROP2, anti-B7-H3, anti-GPR20, anti-CDH6, anti-MUC1, and anti-CD37. In addition, anti-HER2 antibody, anti-HER3 antibody, anti-TROP2 antibody, anti-B7-H3 antibody, anti-GPR20 antibody, anti-CDH6 antibody and anti-MUC1 antibody can be preferably exemplified.
[1032] In the present invention, the term "anti-HER2 antibody" refers to an antibody that specifically binds to HER2 (human epidermal growth factor receptor type 2; ErbB-2) and preferably has an activity of internalizing in HER2-expressing cells by binding to HER2.
[1033] Examples of anti-HER2 antibodies include trastuzumab (U.S. Pat. No. 5,821,337) and pertuzumab (International Publication No. WO 01 / 00245). Preferably, trastuzumab can be exemplified.
[1034] In the present invention, the term "anti-HER3 antibody" refers to an antibody that specifically binds to HER3 (human epidermal growth factor receptor type 3; ErbB-3) and preferably has an activity of internalization in HER3-expressing cells by binding to HER3.
[1035] Examples of anti-HER3 antibodies include Pertuzumab (U3-1287), U1-59 (International Publication No. WO 2007 / 077028), MM-121 (Ceretuzumab), the anti-ERBB3 antibody described in International Publication No. WO 2008 / 100624, RG-7116 (Rutuzumab) and LJM-716 (Eglinutumab). Preferably, Pertuzumab and U1-59 can be exemplified.
[1036] In the present invention, the term "anti-TROP2 antibody" refers to an antibody that specifically binds to TROP2 (TACSTD2: tumor-associated calcium signal transducer 2; EGP-1) and preferably has an activity of internalization in TROP2-expressing cells by binding to TROP2.
[1037] Examples of anti-TROP2 antibodies include hTINA1-H1L1 (International Publication No. WO 2015 / 098099).
[1038] In the present invention, the term "anti-B7-H3 antibody" refers to an antibody that specifically binds to B7-H3 (B cell antigen #7 homolog 3; PD-13; CD276) and preferably has the activity of internalization in B7-H3 expressing cells by binding to B7-H3.
[1039] Examples of anti-B7-H3 antibodies include M30-H1-L4 (International Publication No. WO 2014 / 057687).
[1040] In the present invention, the term "anti-GPR20 antibody" refers to an antibody that specifically binds to GPR20 (G protein coupled receptor 20) and preferably has an activity of internalizing in GPR20-expressing cells by binding to GPR20.
[1041] Examples of anti-GPR20 antibodies include h046-H4e / L7 (International Publication No. WO 2018 / 135501).
[1042] In the present invention, the term "anti-CDH6 antibody" refers to an antibody that specifically binds to CDH6 (Cadherin-6) and preferably has an activity of internalizing in CDH6-expressing cells by binding to CDH6.
[1043] Examples of anti-CDH6 antibodies include H01L02 (International Publication No. WO 2018 / 212136).
[1044] In the present invention, the term "anti-MUC1 antibody" refers to an antibody that specifically binds to MUC1 (Mucin 1) and preferably has an activity of internalizing in MUC1-expressing cells by binding to MUC1.
[1045] Examples of anti-MUC1 antibodies include PankoMab (Danielczyk, A. et al. (2006) Cancer Immunol. Immunother. 55, 1337-1347) and a PankoMab variant (PM-N54Q) disclosed in International Publication No. WO 2019 / 21989.
[1046] In the present invention, the term "anti-CD37 antibody" refers to an antibody that specifically binds to CD37 and preferably has an activity of internalizing in CD37-expressing cells by binding to CD37.
[1047] Examples of anti-CD37 antibodies include, but are not limited to: an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:16 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19; an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:17 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19; or an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19.
[1048] 3. Preparation of Antibody-Drug Conjugates
[1049] The drug-linker intermediate used to prepare the antibody-drug conjugate according to the present invention is represented by the following formula.
[1050] [Formula 90]
[1051]
[1052] The drug-linker intermediate can be represented by the chemical name N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycylglycyl-L-phenylalanyl-N-[(2-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino}-2-oxoethoxy)methyl]glycineamide, and reference can be made to International Publication Nos. WO 2014 / 057687, WO 2015 / 098099, WO 2016 / 09999, WO 2017 / 099999, WO 2018 / 0999999, WO 2019 / 09999999, WO 2020 / 09 ... The method is prepared according to the description in WO 2015 / 115091, International Publication No. WO 2015 / 155998, International Publication No. WO 2019 / 044947, etc.
[1053] The antibody-drug conjugate used in the present invention can be prepared by reacting the above-mentioned drug-linker intermediate with an antibody having a thiol group (alternatively referred to as a sulfhydryl group).
[1054] Antibodies with sulfhydryl groups can be obtained by methods well known in the art (Hermanson, GT, Bioconjugate Techniques, pp. 56-136, pp. 456-493, Academic Press (1996)). For example, using 0.3 to 3 molar equivalents of a reducing agent such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP) for each interchain disulfide bond in the antibody and reacting with the antibody in a buffer solution containing a chelating agent such as ethylenediaminetetraacetic acid (EDTA), an antibody with sulfhydryl groups and partially or completely reduced interchain disulfide bonds in the antibody can be obtained.
[1055] In addition, by using 2 to 20 molar equivalents of the drug-linker intermediate per antibody having a thiol group, an antibody-drug conjugate in which 2 to 8 drug molecules are conjugated per antibody molecule can be prepared.
[1056] For example, the average number of conjugated drug molecules per antibody molecule of the prepared antibody-drug conjugate can be determined by a calculation method based on measuring the ultraviolet absorbance of the antibody-drug conjugate and its conjugation precursor at two wavelengths of 280 nm and 370 nm (ultraviolet method), or a calculation method based on quantification by HPLC measurement of fragments obtained by treating the antibody-drug conjugate with a reducing agent (HPLC method).
[1057] The conjugation between the antibody and the drug-linker intermediate and the calculation of the average number of conjugated drug molecules per antibody molecule of the antibody-drug conjugate can be carried out with reference to the description in International Publication No. WO 2014 / 057687, International Publication No. WO 2015 / 098099, International Publication No. WO 2015 / 115091, International Publication No. WO 2015 / 155998, International Publication No. WO 2018 / 135501 and International Publication No. WO 2018 / 212136, etc.
[1058] In the present invention, the term "anti-HER2 antibody-drug conjugate" refers to an antibody-drug conjugate such that the antibody in the antibody-drug conjugate according to the present invention is an anti-HER2 antibody.
[1059] The anti-HER2 antibody is preferably an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDRH1 (SEQ ID NO: 20) consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO: 1; CDRH2 (SEQ ID NO: 21) consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO: 1 and CDRH3 (SEQ ID NO: 22) consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO: 1; the light chain comprises CDRL1 (SEQ ID NO: 23) consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO: 2; CDRL2 (SEQ ID NO: 24) consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO: 2 and CDRL3 (SEQ ID NO: 25) consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO: 2; and more preferably comprises an antibody comprising a heavy chain comprising a heavy chain variable region (SEQ ID NO: 26) consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO: 1. NO:26), wherein the light chain comprises a light chain variable region (SEQ ID NO:27) consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:2; even more preferably, an antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO:1 and a light chain consisting of an amino acid sequence shown in SEQ ID NO:2, or an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1 and a light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:2.
[1060] The average number of drug-linker units conjugated per antibody molecule in the anti-HER2 antibody-drug conjugate is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, even more preferably about 8.
[1061] The anti-HER2 antibody-drug conjugate can be prepared with reference to the description in International Publication No. WO 2015 / 115091 and the like.
[1062] One such antibody-drug conjugate is trastuzumab (DS-8201a), which consists of a HER2 targeting antibody and a derivative of exotecan. In particular, WO 2015 / 115091 provides a detailed description of exemplary HER2 targeting antibody-drug conjugates, including trastuzumab (DS-8201a).
[1063] In the present invention, the term "anti-HER3 antibody-drug conjugate" refers to an antibody-drug conjugate such that the antibody in the antibody-drug conjugate according to the present invention is an anti-HER3 antibody.
[1064] The anti-HER3 antibody is preferably an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 35 of SEQ ID NO:3, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 50 to 65 of SEQ ID NO:3, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 98 to 106 of SEQ ID NO:3; the light chain comprises CDRL1 consisting of an amino acid sequence consisting of amino acid residues 24 to 39 of SEQ ID NO:4, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 56 to 62 of SEQ ID NO:4, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 95 to 103 of SEQ ID NO:4; more preferably, an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 117 of SEQ ID NO:3; the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO:4; and even more preferably, a heavy chain consisting of an amino acid sequence shown in SEQ ID NO:3 and a light chain variable region consisting of an amino acid sequence shown in SEQ ID NO:4. An antibody having a light chain consisting of the amino acid sequence shown in NO:4; or an antibody variant in which the lysine residue at the carboxyl terminus of the heavy chain is deleted.
[1065] The average number of drug-linker units conjugated per antibody molecule in the anti-HER3 antibody-drug conjugate is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, even more preferably about 8.
[1066] The anti-HER3 antibody-drug conjugate can be prepared with reference to the description in International Publication No. WO 2015 / 155998 and the like.
[1067] In the present invention, the term "anti-TROP2 antibody-drug conjugate" refers to an antibody-drug conjugate such that the antibody in the antibody-drug conjugate according to the present invention is an anti-TROP2 antibody.
[1068] The anti-TROP2 antibody is preferably an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDRH1 (SEQ ID NO:28) consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5; CDRH2 (SEQ ID NO:29) consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5 and CDRH3 (SEQ ID NO:30) consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; the light chain comprises CDRL1 (SEQ ID NO:31) consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6; CDRL2 (SEQ ID NO:32) consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6 and CDRL3 (SEQ ID NO:33) consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6; more preferably, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises a CDRH1 (SEQ ID NO:32) consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6 and a CDRL3 (SEQ ID NO:33) consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:6. NO:5 comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5 (SEQ ID NO:34); the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:6 (SEQ ID NO:35); and even more preferably comprises an antibody with a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:6; or an antibody variant in which the lysine residue at the carboxyl terminus of the heavy chain is deleted.
[1069] The average number of drug-linker units conjugated per antibody molecule in the anti-TROP2 antibody-drug conjugate is preferably 2 to 8, more preferably 3 to 5, even more preferably 3.5 to 4.5, even more preferably about 4.
[1070] The anti-TROP2 antibody-drug conjugate can be prepared with reference to the description in International Publication No. WO 2015 / 098099 and International Publication No. WO 2017 / 002776.
[1071] One such antibody-drug conjugate is dedabotulinumab, which consists of a TROP2 targeting antibody and a derivative of exotecan. In particular, WO 2015 / 098099 and WO 2020 / 240467 provide detailed descriptions of exemplary TROP2 targeting antibody-drug conjugates, including dedabotulinumab (DS-1062).
[1072] In the present invention, the term "anti-B7-H3 antibody-drug conjugate" refers to an antibody-drug conjugate such that the antibody in the antibody-drug conjugate according to the present invention is an anti-B7-H3 antibody.
[1073] The anti-B7-H3 antibody is preferably an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:7, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:7, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 130 of SEQ ID NO:7; the light chain comprises CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 53 of SEQ ID NO:8, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 69 to 75 of SEQ ID NO:8, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 108 to 116 of SEQ ID NO:8; more preferably, an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 141 of SEQ ID NO:7; the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO:8; and even more preferably comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO:8. An antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:8; or an antibody variant in which the lysine residue at the carboxyl terminus of the heavy chain is deleted.
[1074] The average number of drug-linker units conjugated per antibody molecule in the anti-B7-H3 antibody-drug conjugate is preferably 2 to 8, more preferably 3 to 5, even more preferably 3.5 to 4.5, and even more preferably about 4.
[1075] The anti-B7-H3 antibody-drug conjugate used in the present invention can be prepared with reference to the description in International Publication No. WO 2014 / 057687 and International Publication No. WO 2017 / 002776.
[1076] In the present invention, the term "anti-GPR20 antibody-drug conjugate" refers to an antibody-drug conjugate such that the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
[1077] The anti-GPR20 antibody is preferably an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDRH1 consisting of an amino acid sequence consisting of amino acid residues 45 to 54 of SEQ ID NO:9, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 78 of SEQ ID NO:9, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 131 of SEQ ID NO:9; the light chain comprises CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:10, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:10, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:10; more preferably, an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 142 of SEQ ID NO:9; the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:10; and even more preferably, an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 142 of SEQ ID NO:9; the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:10. An antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:10; or an antibody variant in which the lysine residue at the carboxyl terminus of the heavy chain is deleted.
[1078] The average number of drug-linker units conjugated per antibody molecule in the anti-GPR20 antibody-drug conjugates used in the present invention is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, even more preferably about 8.
[1079] The anti-GPR20 antibody-drug conjugate used in the present invention can be prepared with reference to the description in International Publication No. WO 2018 / 135501, etc.
[1080] In the present invention, the term "anti-CDH6 antibody-drug conjugate" refers to an antibody-drug conjugate such that the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
[1081] The anti-CDH6 antibody is preferably an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDRH1 consisting of an amino acid sequence consisting of amino acid residues 45 to 54 of SEQ ID NO: 11, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 78 of SEQ ID NO: 11, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 130 of SEQ ID NO: 11; the light chain comprises CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO: 12, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO: 12, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 116 of SEQ ID NO: 12; more preferably, an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 141 of SEQ ID NO: 11; the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 12; and even more preferably, an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 141 of SEQ ID NO: 11; the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 12. An antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:12; or an antibody variant in which the lysine residue at the carboxyl terminus of the heavy chain is deleted.
[1082] The average number of drug-linker units conjugated per antibody molecule in the anti-CDH6 antibody-drug conjugates used in the present invention is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, even more preferably about 8.
[1083] The anti-CDH6 antibody-drug conjugate used in the present invention can be prepared with reference to the description in International Publication No. WO 2018 / 212136, etc.
[1084] In the present invention, the term "anti-MUC1 antibody-drug conjugate" refers to an antibody-drug conjugate such that the antibody in the antibody-drug conjugate according to the present invention is an anti-MUC1 antibody.
[1085] The anti-MUC1 antibody is preferably an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDRH1 consisting of an amino acid sequence consisting of amino acid residues 31 to 35 of SEQ ID NO: 13, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 50 to 65 of SEQ ID NO: 13, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 101 to 106 of SEQ ID NO: 13; the light chain comprises CDRL1 consisting of an amino acid sequence consisting of amino acid residues 24 to 39 of SEQ ID NO: 15, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 55 to 61 of SEQ ID NO: 15, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 94 to 102 of SEQ ID NO: 15; more preferably, an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 117 of SEQ ID NO: 13; the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO: 15; and even more preferably, an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO: 15. An antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 447 of SEQ ID NO:13 and a light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 219 of SEQ ID NO:15; or an antibody variant in which the lysine residue at the carboxyl terminus of the heavy chain is deleted.
[1086] Alternatively, the anti-MUC1 antibody is preferably an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 31 to 35 of SEQ ID NO: 14, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 50 to 65 of SEQ ID NO: 14, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 101 to 106 of SEQ ID NO: 14; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 24 to 39 of SEQ ID NO: 15, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 55 to 61 of SEQ ID NO: 15, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 94 to 102 of SEQ ID NO: 15; more preferably an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 117 of SEQ ID NO: 14; the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO: 15; and even more preferably comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 114 of SEQ ID NO: 15. An antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 447 of SEQ ID NO:14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 219 of SEQ ID NO:15; or an antibody variant in which the lysine residue at the carboxyl terminus of the heavy chain is deleted.
[1087] The average number of drug-linker units conjugated per antibody molecule in the anti-MUC1 antibody-drug conjugate is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, even more preferably about 8.
[1088] The anti-MUC1 antibody-drug conjugate can be prepared with reference to the description in International Publication No. WO 2019 / 219891 and the like.
[1089] In the present invention, the term "anti-CD37 antibody-drug conjugate" refers to an antibody-drug conjugate such that the antibody in the antibody-drug conjugate according to the present invention is an anti-CD37 antibody.
[1090] The anti-CD37 antibody is preferably an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDRH1 consisting of an amino acid sequence consisting of amino acid residues 45 to 54 of SEQ ID NO: 16, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 78 of SEQ ID NO: 16, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 127 of SEQ ID NO: 16; the light chain comprises CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO: 19, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO: 19, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO: 19; more preferably, an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 16; the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19; and even more preferably comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19. An antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:16 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19; or an antibody variant in which the lysine residue at the carboxyl terminus of the heavy chain is deleted.
[1091] Alternatively, the anti-CD37 antibody is preferably an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 45 to 54 of SEQ ID NO: 17, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 78 of SEQ ID NO: 17, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 127 of SEQ ID NO: 17; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO: 19, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO: 19, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO: 19; more preferably, the antibody comprises a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 17; the light chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 17 NO:19; and even more preferably an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:17 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19; or an antibody variant in which the lysine residue at the carboxyl terminus of the heavy chain is deleted.
[1092] In addition, the anti-CD37 antibody is preferably an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 45 to 54 of SEQ ID NO: 18, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 78 of SEQ ID NO: 18, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 127 of SEQ ID NO: 18; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO: 19, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO: 19, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO: 19; more preferably an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 18; the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19; and even more preferably comprising a heavy chain and a light chain. An antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:19; or an antibody variant in which the lysine residue at the carboxyl terminus of the heavy chain is deleted.
[1093] The average number of drug-linker units conjugated per antibody molecule in the anti-CD37 antibody-drug conjugate is preferably 2 to 8, more preferably 5 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, even more preferably about 8.
[1094] The anti-CD37 antibody-drug conjugate can be prepared using a preparation method similar to the preparation method described in the patent specifications mentioned in the previous section for anti-HER2 antibody, anti-HER3 antibody, anti-TROP2 antibody, anti-B7-H3 antibody, anti-GPR20 antibody, anti-CDH6 antibody and anti-MUC1 antibody.
[1095] The anti-CD37 antibody-drug conjugate can be used to treat any cancer in which CD37 is expressed. Examples of cancer include, but are not limited to, B-cell non-Hodgkin lymphoma (NHL) (e.g., diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and Burkitt's lymphoma (BL)), chronic lymphocytic leukemia (CLL), T-cell lymphoma (TCL) (e.g., peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL)), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). Other examples of cancer include, but are not limited to, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL).
[1096] 4. EZH1 inhibitors, EZH2 inhibitors and EZH1 / 2 dual inhibitors
[1097] In the present invention, the "EZH1 inhibitor" is a drug having a function of inhibiting EZH1 (enhancer of zeste homolog 1).
[1098] In one embodiment of the present invention, the EZH1 inhibitor has an inhibitory effect on the histone methyltransferase activity of human EZH1, and its IC 50 The IC may be 1 μM or less, 500 nM or less, 400 nM or less, 300 nM or less, 200 nM or less, 150 nM or less, 100 nM or less, 90 nM or less, 80 nM or less, 70 nM or less, 60 nM or less, 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 15 nM or less, or 10 nM or less. Based on the methods described in, for example, WO2015 / 141616, Experimental Example 1, the IC may be determined. 50 For example, by detecting the inhibitory effect on the activity of EZH1 transferring tritium-labeled S-adenosylmethionine to a peptide having an EZH1 target sequence (e.g., a sequence of the 12th to 40th amino acids of a human histone H3 protein; for the amino acid sequence of a human histone H3 protein, see, for example, a sequence registered under GenBank Accession No.: CAB02546.1). Using the PRC2-EZH1 complex, the methyltransferase activity of EZH1 can be measured.
[1099] Examples of EZH1 inhibitors that can be used in the present invention include, but are not particularly limited to:
[1100] (2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide,
[1101] Valmetofarat (IUPAC name: (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide) and pharmaceutically acceptable salts of these compounds.
[1102] In the present invention, the "EZH2 inhibitor" is a drug having a function of inhibiting EZH2.
[1103] In one embodiment of the present invention, the EZH2 inhibitor has an inhibitory effect on the histone methyltransferase activity of human EZH2, and its IC 50 The IC may be 1 μM or less, 500 nM or less, 400 nM or less, 300 nM or less, 200 nM or less, 150 nM or less, 100 nM or less, 90 nM or less, 80 nM or less, 70 nM or less, 60 nM or less, 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 15 nM or less, or 10 nM or less. Based on the methods described in, for example, WO2015 / 141616, Experimental Example 2, the IC may be determined. 50 For example, by detecting the inhibitory effect on the activity of EZH2 transferring tritium-labeled S-adenosylmethionine to a peptide having an EZH2 target sequence (e.g., a sequence of the 12th to 40th amino acids of a human histone H3 protein; regarding the amino acid sequence of a human histone H3 protein, see, e.g., a sequence registered under GenBank Accession No.: CAB02546.1). Using the PRC2-EZH2 complex, the EZH2 methyltransferase activity can be measured.
[1104] Examples of EZH2 inhibitors that can be used in the present invention include, but are not particularly limited to:
[1105] N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide,
[1106] N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide,
[1107] (2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide,
[1108] Valmetofarat (IUPAC name: (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide), and pharmaceutically acceptable salts of these compounds.
[1109] Examples of EZH2 inhibitors that can be used in the present invention include (1S,2R,5R)-5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol and pharmaceutically acceptable salts thereof.
[1110] Examples of EZH2 inhibitors that can be used in the present invention further include N-[(6-methyl-2-oxo-4-propyl-1H-pyridin-3-yl)methyl]-1-propan-2-yl-6-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]indazole-4-carboxamide and pharmaceutically acceptable salts thereof.
[1111] Examples of EZH2 inhibitors further include tazestat (IUPAC name: N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide) (E7438 or EPZ-6438) and pharmaceutically acceptable salts thereof. The compound is disclosed in Example 44 of WO2012 / 142504.
[1112] Examples of EZH2 inhibitors further include Lirametostat (CPI-1205) and pharmaceutically acceptable salts thereof.
[1113] Examples of EZH2 inhibitors further include N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide (GSK126) and pharmaceutically acceptable salts thereof disclosed in Example 270 of WO2011 / 140324.
[1114] Examples of EZH2 inhibitors that can be used in the present invention further include N-[(1,2-dihydro-6-methyl-2-oxo-4-propyl-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indazole-4-carboxamide and pharmaceutically acceptable salts thereof.
[1115] Examples of EZH2 inhibitors that can be used in the present invention further include various compounds described in Stazi, G. et al., Expert Opinion on Therapeutic Patents, 27:7, 797-813, 2017. EZH2 inhibitors are known; for example, EZH2 inhibitors described in the following documents can be used in the present invention: WO2014 / 100646, WO2015 / 057859, WO2016 / 081523, WO2014 / 144747, WO2015 / 010078, WO2015 / 010049, WO2015 / 200650, WO2015 / 132765, WO2015 / 004618, W O2016 / 066697、WO2014 / 124418、WO2015 / 023915、WO2016 / 130396、WO2015 / 077193、WO2015 / 077194、 WO2015 / 193768, WO2016 / 073956, WO2016 / 073903, WO2016 / 102493, WO2016 / 089804, WO2014 / 151369.
[1116] In the present invention, the EZH2 inhibitor may further have an EZH1 inhibitory effect, and may be, for example, an EZH1 / 2 dual inhibitor. For example, the aforementioned N-[(6-methyl-2-oxo-4-propyl-1H-pyridin-3-yl)methyl]-1-propane-2-yl-6-[6-(4-propane-2-ylpiperazine-1-yl)pyridin-3-yl]indazole-4-carboxamide and a pharmaceutically acceptable salt thereof may be an EZH1 / 2 dual inhibitor.
[1117] In one embodiment of the present invention, the EZH1 / 2 dual inhibitor has an inhibitory effect on the histone methyltransferase activity of human EZH1, and its IC 50 The compound may be 1 μM or less, 500 nM or less, 400 nM or less, 300 nM or less, 200 nM or less, 150 nM or less, 100 nM or less, 90 nM or less, 80 nM or less, 70 nM or less, 60 nM or less, 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 15 nM or less or 10 nM or less, and has an inhibitory effect on the histone methyltransferase activity of human EZH2, and its IC 50 Can be 1 μM or less, 500 nM or less, 400 nM or less, 300 nM or less, 200 nM or less, 150 nM or less, 100 nM or less, 90 nM or less, 80 nM or less, 70 nM or less, 60 nM or less, 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 15 nM or less or 10 nM or less. IC of EZH1 and EZH2 50 The values can each be determined as described above.
[1118] Examples of EZH1 / 2 dual inhibitors that can be used in the present invention include, but are not particularly limited to:
[1119] (2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide,
[1120] Valmetofarat (IUPAC name: (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide), and pharmaceutically acceptable salts of these compounds.
[1121] (2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide is disclosed in Example 15 of WO2015 / 141616 and is a compound having the following structure:
[1122] [Formula 91]
[1123]
[1124] Valmetositol (IUPAC name: (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide) (DS-3201a) is disclosed in Example 35 of WO2015 / 141616 and is a compound having the following structure:
[1125] [Formula 92]
[1126]
[1127] Valmettostat tosylate (IUPAC name: (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide p-toluenesulfonate) (DS-3201b) (also referred to as "Compound A" in this patent specification) is disclosed in Example 80 of WO2015 / 141616. Compound A can be prepared by referring to the synthesis method disclosed in WO2015 / 141616.
[1128] In the present invention, the inhibitor selected from EZH1 inhibitor, EZH2 inhibitor and EZH1 / 2 dual inhibitor may be present in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salt includes an acid addition salt or a salt with a base, but is preferably an acid addition salt, examples of which may include lower alkane sulfonates such as camphorsulfonate (camsilate, camphorsulfonate), methanesulfonate, trifluoromethanesulfonate and ethanesulfonate; aryl sulfonates such as toluenesulfonate (p-toluenesulfonate) and benzenesulfonate; inorganic acid salts such as phosphates, nitrates, perchlorates and bisulfates; hydrohalide salts such as hydrochlorides, hydrobromides, hydroiodides and hydrofluorides; organic acid salts such as acetates, malates, fumarates, succinates, citrates, tartrates, oxalates and maleates; and amino acid salts such as ornithine, glutamate and aspartate.
[1129] In addition, the inhibitor selected from EZH1 inhibitor, EZH2 inhibitor and EZH1 / 2 dual inhibitor and its pharmaceutically acceptable salt may also exist in the form of a solvate. For clarification, the solvate may be a solvate of a pharmaceutically acceptable salt of the inhibitor selected from EZH1 inhibitor, EZH2 inhibitor and EZH1 / 2 dual inhibitor.
[1130] 5. Medication
[1131] The following describes pharmaceutical products and methods of treatment according to the invention, wherein an antibody-drug conjugate is administered in combination with an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor.
[1132] The pharmaceutical products and treatment methods of the present invention may be those in which the antibody-drug conjugate and the inhibitor selected from the group consisting of EZH1 inhibitors, EZH2 inhibitors and EZH1 / 2 dual inhibitors are respectively contained in different preparations as active ingredients and are administered simultaneously or at different times, or may be those in which the antibody-drug conjugate and the inhibitor selected from the group consisting of EZH1 inhibitors, EZH2 inhibitors and EZH1 / 2 dual inhibitors are contained in a single preparation as active ingredients and administered. When the antibody-drug conjugate and the inhibitor selected from the group consisting of EZH1 inhibitors, EZH2 inhibitors and EZH1 / 2 dual inhibitors are respectively contained in different preparations as active ingredients, the antibody-drug conjugate and the inhibitor selected from the group consisting of EZH1 inhibitors, EZH2 inhibitors and EZH1 / 2 dual inhibitors may be administered at different intervals.
[1133] The term "drug product" means a preparation in a form that allows the active ingredients to exert their biological activity, either as a composition containing all the active ingredients (for simultaneous administration), or as a combination of separate compositions each containing at least one but not all of the active ingredients (for sequential or simultaneous administration) (combination preparation). r And it contains no additional components that are unacceptably toxic to the subject to which the product is to be administered.Such a product may be sterile.
[1134] The pharmaceutical product and treatment method of the present invention can be used to treat cancer, and can preferably be used to treat at least one disease selected from the following: breast cancer (including triple-negative breast cancer and luminal breast cancer), gastric cancer (also known as gastric adenocarcinoma), colorectal cancer (also known as colon and rectal cancer, and including colon cancer and rectal cancer), lung cancer (including small cell lung cancer and non-small cell lung cancer), esophageal cancer, head and neck cancer (including salivary gland cancer and pharyngeal cancer), gastroesophageal junction adenocarcinoma, biliary cancer (including bile duct cancer), Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinoma, urinary tract cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumors, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, renal cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, non-Hodgkin lymphoma (e.g., diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Burkitt lymphoma (BL)), chronic lymphocytic leukemia, T-cell lymphoma (TCL) (e.g., peripheral T-cell lymphoma and may be more preferably used to treat at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer and sarcoma; and may be more preferably used to treat to The invention can be used to treat at least one cancer selected from the group consisting of non-Hodgkin lymphoma (e.g., diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Burkitt lymphoma (BL)) and chronic lymphocytic leukemia; and can be more preferably used to treat at least one cancer selected from the group consisting of T-cell lymphoma (TCL) (e.g., peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL)) and acute myeloblastic leukemia (AML).
[1135] In one embodiment, the pharmaceutical product and treatment method of the present invention can be used to treat breast cancer. In another embodiment, the pharmaceutical product and treatment method of the present invention can be used to treat triple negative breast cancer. In another embodiment, the pharmaceutical product and treatment method of the present invention can be used to treat HER2 low expression breast cancer.
[1136] In one embodiment, the pharmaceutical products and methods of treatment of the present invention may be used to treat lung cancer. In another embodiment, the pharmaceutical products and methods of treatment of the present invention may be used to treat non-small cell lung cancer.
[1137] In one embodiment, the pharmaceutical products and methods of treatment of the present invention may be used to treat non-Hodgkin lymphoma. In another embodiment, the pharmaceutical products and methods of treatment of the present invention may be used to treat diffuse large B-cell lymphoma (DLBCL).
[1138] In one embodiment, the pharmaceutical products and therapeutic methods of the present invention may be used to treat prostate cancer.
[1139] In one embodiment, the pharmaceutical products and therapeutic methods of the present invention may be used to treat ovarian cancer.
[1140] In the antibody-drug conjugate used in the present invention, the type of antibody preferably used in the antibody-drug conjugate can be determined by examining the type of cancer and tumor markers. For example, in the case where HER2 expression is found in cancer, anti-HER2 antibody-drug conjugates can be preferably used; in the case where HER3 expression is found in cancer, anti-HER3 antibody-drug conjugates can be preferably used; in the case where TROP2 expression is found in cancer, anti-TROP2 antibody-drug conjugates can be preferably used; in the case where B7-H3 expression is found in cancer, anti-B7-H3 antibody-drug conjugates can be preferably used; in the case where GPR20 expression is found in cancer, anti-GPR20 antibody-drug conjugates can be preferably used; in the case where CDH6 expression is found in cancer, anti-CDH6 antibody-drug conjugates can be preferably used; in the case where MUC1 expression is found in cancer, anti-MUC1 antibody-drug conjugates can be preferably used; and in the case where CD37 expression is found in cancer, anti-CD37 antibody-drug conjugates can be preferably used.
[1141] For example, by collecting tumor tissue from a cancer patient and performing a gene product (protein) level examination on a formalin-fixed paraffin-embedded sample (FFPE), such as an immunohistochemistry (IHC) method, flow cytometry, Western blotting, or a gene transcription level examination such as an in situ hybridization method (ISH), a quantitative PCR method (q-PCR), or a microarray analysis, the presence or absence of HER2, HER3, TROP2, B7-H3, GPR20, CDH6, and MUC1 and other tumor markers can be examined; alternatively, it can also be examined as follows: by collecting cell-free blood circulating tumor DNA (ctDNA) from a cancer patient and performing an examination using, for example, a next-generation sequencing (NGS) method. These methods can be applied to the presence or absence of CD37.
[1142] In the case where the antibody-drug conjugate used in the present invention is an anti-HER2 antibody-drug conjugate, the drug product and treatment method of the present invention may preferably be applicable not only to HER2 overexpressing cancers but also to HER2 underexpressing cancers and HER2 mutated cancers.
[1143] In the present invention, the term "HER2 overexpression cancer" is not particularly limited, as long as it is identified as HER2 overexpression cancer by a person skilled in the art. Preferred examples of HER2 overexpression cancers may include cancers with a HER2 expression score of 3+ in an immunohistochemical method, and cancers with a HER2 expression score of 2+ in an immunohistochemical method and determined to be HER2 expression positive in an in situ hybridization method. The in situ hybridization method of the present invention includes a fluorescent in situ hybridization method (FISH) and a dual-color in situ hybridization method (DISH).
[1144] In the present invention, the term "HER2 low-expressing cancer" is not particularly limited, as long as it is recognized as HER2 low-expressing cancer by a person skilled in the art. Preferred examples of HER2 low-expressing cancers may include cancers in which the HER2 expression score is 2+ in the immunohistochemical method and the HER2 expression is determined to be negative in the in situ hybridization method, and cancers in which the HER2 expression score is 1+ in the immunohistochemical method. Another example of HER2 low-expressing cancer may include, but is not particularly limited to, cancers in which the HER2 expression score is >0 and <1+ in the immunohistochemical method.
[1145] The method that HER2 expression degree is scored by immunohistochemical method or the method that HER2 expression is carried out positive or negative judgment by in situ hybridization method is not particularly limited, as long as those skilled in the art approve.The example of described method can be included in the method described in breast cancer HER2 test guide the 4th edition (being formulated by Japanese Pathology Board for Optimal Use of HER2 for Breast Cancer) of Japanese breast cancer HER2.
[1146] The HER2-low expressing cancer for which the pharmaceutical product and treatment method of the present invention can be used is preferably HER2-low expressing breast cancer, HER2-low expressing gastric cancer, HER2-low expressing colorectal cancer or HER2-low expressing non-small cell lung cancer, and more preferably HER2-low expressing breast cancer.
[1147] The pharmaceutical products and methods of treatment of the present invention may preferably be used in mammals, and may more preferably be used in humans.
[1148] The pharmaceutical products and methods of treatment of the present invention can preferably be used for maintenance therapy. The pharmaceutical products and methods of treatment of the present invention can be used to prevent tumor recurrence after initial chemotherapy.
[1149] In the present invention, the term "maintenance therapy" means treatment to help prevent cancer from returning after the cancer has disappeared after initial treatment. The term is defined based on "maintenance therapy" in the following references.
[1150] NCIDictionaries, "maintenance therapy", NCIDictionary of Cancer Terms [online]. National Cancer Institute [retrieved on 2023-04-10].<cancer.gov / publications / dictionaries / cancer-terms / def / maintenance-therapy> Retrieve.
[1151] The anti-tumor effect of the pharmaceutical product and the method of treatment of the present invention can be confirmed by, for example, generating a model in which cancer cells are transplanted into a test animal and measuring the reduction in tumor volume, the life extension effect achieved by applying the pharmaceutical product and the method of treatment of the present invention. In addition, the combined effect of the antibody-drug conjugate used in the present invention and the inhibitor selected from the group consisting of the EZH1 inhibitor, the EZH2 inhibitor and the EZH1 / 2 dual inhibitor can be confirmed by comparing the anti-tumor effect of each of the antibody-drug conjugate used in the present invention and the inhibitor selected from the group consisting of the EZH1 inhibitor, the EZH2 inhibitor and the EZH1 / 2 dual inhibitor when each is administered alone.
[1152] In addition, the anti-tumor effects of the pharmaceutical products and treatment methods of the present invention can be confirmed in clinical studies using the RECIST evaluation method, the WHO evaluation method, the Macdonald evaluation method, body weight measurement and other methods; and can be determined by indicators such as complete remission (CR), partial remission (PR), disease progression (PD), objective response rate (ORR), duration of remission (DoR), progression-free survival (PFS) and overall survival (OS).
[1153] The aforementioned methods can demonstrate the superiority of the pharmaceutical products and treatment methods of the present invention in terms of anti-tumor effects compared to existing pharmaceutical products and treatment methods for cancer treatment.
[1154] The pharmaceutical product and the method of treatment of the present invention can delay the growth of cancer cells, inhibit its proliferation, and can further kill cancer cells. These effects can make cancer patients get rid of the symptoms caused by cancer, or can achieve the improvement of the quality of life (QOL) of cancer patients, and achieve the therapeutic effect by maintaining the life of cancer patients. Even if the pharmaceutical product and the method of treatment can not achieve the killing of cancer cells, they can also achieve the higher quality of life (QOL) of cancer patients by inhibiting or controlling the growth of cancer cells, and achieve longer-term survival. In addition, the pharmaceutical product and the method of treatment of the present invention can show a sustained anti-tumor effect.
[1155] The pharmaceutical products and methods of treatment of the present invention are not associated with severe weight loss.
[1156] The pharmaceutical product of the present invention may be expected to exert a therapeutic effect through systemic treatment of the patient and additionally be expected to exert a therapeutic effect through local application to cancerous tissue.
[1157] The pharmaceutical product of the present invention includes a pharmaceutical composition containing at least one pharmaceutically suitable ingredient. According to the dosage, application concentration, etc. of the antibody-drug conjugate used in the present invention and the inhibitor selected from EZH1 inhibitors, EZH2 inhibitors and EZH1 / 2 dual inhibitors, the pharmaceutically suitable ingredients can be appropriately selected and applied from the formulation additives commonly used in the art, etc. For example, the antibody-drug conjugate used in the present invention can be used as a pharmaceutical product containing a buffer (such as a histidine buffer), an excipient (such as sucrose or trehalose) and a surfactant (such as polysorbate 80 or 20). The pharmaceutical product containing the antibody-drug conjugate used in the present invention can be preferably used as an injection, can be more preferably used as an aqueous injection or a lyophilized injection, and can be even more preferably used as a lyophilized injection.
[1158] In the case where the drug product containing the antibody-drug conjugate used in the present invention is an aqueous injection, it can be preferably diluted with a suitable diluent and then administered as an intravenous infusion. As for the diluent, dextrose solution, physiological saline, etc. can be exemplified, dextrose solution can be preferably exemplified, and 5% dextrose solution can be more preferably exemplified.
[1159] In the case where the drug product containing the antibody-drug conjugate used in the present invention is a lyophilized injection, it can be preferably dissolved in water for injection, and then the required amount can be diluted with a suitable diluent and then administered as an intravenous infusion. As for the diluent, dextrose solution, physiological saline, etc. can be exemplified, dextrose solution can be preferably exemplified, and 5% dextrose solution can be more preferably exemplified.
[1160] Examples of administration routes that can be used to administer the pharmaceutical product of the present invention include intravenous, intradermal, subcutaneous, intramuscular, and intraperitoneal routes; and preferably include the intravenous route.
[1161] The antibody-drug conjugate used in the present invention can be administered to a human once at intervals of 1 to 180 days, preferably once a week, once every 2 weeks, once every 3 weeks, or once every 4 weeks, and even more preferably once every 3 weeks. In addition, the antibody-drug conjugate used in the present invention can be administered at a dose of about 0.001 to 100 mg / kg, preferably at a dose of 0.8 to 12.4 mg / kg. In the case where the antibody-drug conjugate used in the present invention is an anti-HER2 antibody-drug conjugate, it can be preferably administered once every 3 weeks at a dose of 0.8 mg / kg, 1.6 mg / kg, 3.2 mg / kg, 5.4 mg / kg, 6.4 mg / kg, 7.4 mg / kg or 8 mg / kg. In the case where the antibody-drug conjugate used in the present invention is an anti-HER3 antibody-drug conjugate, it may preferably be administered once every 3 weeks at a dose of 1.6 mg / kg, 3.2 mg / kg, 4.8 mg / kg, 5.6 mg / kg, 6.4 mg / kg, 8.0 mg / kg, 9.6 mg / kg or 12.8 mg / kg. In the case where the antibody-drug conjugate used in the present invention is an anti-TROP2 antibody-drug conjugate, it may preferably be administered once every 3 weeks at a dose of 0.27 mg / kg, 0.5 mg / kg, 1.0 mg / kg, 2.0 mg / kg, 4.0 mg / kg, 6.0 mg / kg or 8.0 mg / kg.
[1162] The dosage of the inhibitor selected from EZH1 inhibitor, EZH2 inhibitor and EZH1 / 2 dual inhibitor according to the present invention is not particularly limited, as long as it is an effective amount for treating the target disease, and is appropriately selected according to the patient's age, weight, symptoms, health status and disease progression. The frequency of administration is not particularly limited, and can be appropriately selected according to the purpose. For example, the daily dose is administered once a day or divided into multiple doses and administered separately. When the medicament of the present invention is administered to a human, the dosage range of the active ingredient is from about 0.01 mg / kg (body weight) to about 500 mg / kg (body weight), preferably from about 0.1 mg / kg (body weight) to about 100 mg / kg (body weight). For administration to a human, it is preferred that the daily dose is administered once a day or divided into 2-4 portions and administered separately at appropriate intervals.
[1163] The pharmaceutical products and treatment methods of the present invention may further contain cancer therapeutic agents other than the antibody-drug conjugate according to the present invention and an inhibitor selected from EZH1 inhibitors, EZH2 inhibitors and EZH1 / 2 dual inhibitors. The pharmaceutical products and treatment methods of the present invention may also be administered in combination with other cancer therapeutic agents to enhance the anti-tumor effect. Other cancer therapeutic agents for such purposes may be administered to a subject simultaneously, separately or sequentially with the pharmaceutical composition of the present invention, or may be administered at different intervals for each administration. Such cancer therapeutic agents are not limited as long as they are agents having antitumor activity, and may be exemplified by at least one selected from the group consisting of irinotecan (CPT-11), cisplatin, carboplatin, oxaliplatin, fluorouracil (5-FU), gemcitabine, capecitabine, paclitaxel, docetaxel, doxorubicin, epirubicin, cyclophosphamide, mitomycin C, tegafur-gimeracil-oteracil combination, cetuximab, panitumumab, bevacizumab, ramucirumab, regorafenib, trifluridine-tipiracil combination, gefitinib, erlotinib, afatinib, methotrexate, pemetrexed, tamoxifen, toremifene, fulvestrant, leuprolide, goserelin, letrozole, anastrozole, progesterone preparations, trastuzumab, pertuzumab, and lapatinib.
[1164] The pharmaceutical products and treatment methods of the present invention can also be used in combination with radiotherapy. For example, a cancer patient can receive radiotherapy before and / or after or simultaneously with treatment with the pharmaceutical products of the present invention.
[1165] The pharmaceutical products and treatment methods of the present invention can also be used as adjuvant chemotherapy in combination with surgery. The pharmaceutical products of the present invention can be administered before surgery to reduce tumor size (called preoperative adjuvant chemotherapy or neoadjuvant therapy), or can be administered after surgery to prevent tumor recurrence (called postoperative adjuvant chemotherapy or adjuvant therapy). Example
[1166] The present invention is specifically described with reference to the examples shown below. However, the present invention is not limited to these examples. Further, they should never be interpreted in a restrictive manner.
[1167] Example 1: Preparation of anti-HER2 antibody-drug conjugate (1)
[1168] According to the preparation method described in International Publication No. WO 2015 / 115091, an anti-HER2 antibody (an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO: 2) was used to prepare an anti-HER2 antibody-drug conjugate (hereinafter referred to as "HER2-ADC (1)" (trastuzumab / DS-8201a)), wherein the drug-linker represented by the following formula:
[1169] [Formula 93]
[1170]
[1171] Where A represents the connection position with the antibody,
[1172] Conjugated to anti-HER2 antibody via thioether bond. The DAR of HER2-ADC (1) was 7.7 or 7.8.
[1173] Example 2: Preparation of anti-TROP2 antibody-drug conjugate (1)
[1174] According to the preparation methods described in International Publication Nos. WO 2015 / 098099 and 2017 / 002776, an anti-TROP2 antibody (an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO: 5 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 6) was used to prepare an anti-TROP2 antibody-drug conjugate (hereinafter referred to as "TROP2-ADC (1)"), wherein the drug-linker represented by the following formula:
[1175] [Formula 94]
[1176]
[1177] Where A represents the connection position with the antibody,
[1178] Conjugated to anti-TROP2 antibody via thioether bond. The DAR of TROP2-ADC (1) is 3.5 to 4.5.
[1179] Example 3: Preparation of anti-HER3 antibody-drug conjugate (1)
[1180] According to the preparation method described in International Publication No. WO 2015 / 155998, an anti-HER3 antibody (an antibody comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 4) was used to prepare an anti-HER3 antibody-drug conjugate (hereinafter referred to as "HER3-ADC (1)"), wherein the drug-linker represented by the following formula:
[1181] [Formula 95]
[1182]
[1183] Where A represents the connection position with the antibody,
[1184] Conjugated to anti-HER3 antibody via thioether bond. The DAR of HER3-ADC (1) is 7.6.
[1185] Example 4: Preparation of anti-CDH6 antibody-drug conjugate (1)
[1186] According to the preparation method described in International Publication No. WO 2018 / 212136, an anti-CDH6 antibody (an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 11 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 12) was used to prepare an anti-CDH6 antibody-drug conjugate (hereinafter referred to as "CDH6-ADC (1)"), wherein the drug-linker represented by the following formula:
[1187] [Formula 96]
[1188]
[1189] Where A represents the connection position with the antibody,
[1190] Conjugated to anti-CDH6 antibody via thioether bond. The DAR of CDH6-ADC (1) is 7.8.
[1191] Example 5: Anti-tumor study (1)
[1192] Measurements and calculation formula: In all studies, the long and short axes of the tumors were measured once or twice a week with electronic digital calipers, and the estimated tumor volume (mm 3 ). The calculation formula is as follows:
[1193] Estimated tumor volume (mm 3 )=1 / 2×major axis (mm)×[minor axis (mm)] 2
[1194] Tumor growth inhibition (TGI) was calculated according to the following formula.
[1195] Tumor growth inhibition (%) = 100 × (1-T / C)
[1196] T: Average estimated tumor volume of mice in the test substance administration group
[1197] C: Mean estimated tumor volume of control mice
[1198] HER2-ADC (1) was diluted with ABS buffer (10 mM acetate buffer [pH 5.5], 5% sorbitol) and intravenously administered to the tail vein at a fluid volume of 10 mL / kg. Compound A was orally administered via a feed mixture containing 0.3% of Compound A.
[1199] These methods are the same for Examples 5 to 8 and Examples 11 to 16. In Examples 12 to 16, TROP2-ADC (1), HER3-ADC (1), CD37-ADC (1) or B7-H3-ADC (1) was used for evaluation. In addition, in Examples 12 to 16, Compound A was orally administered via a feed mixture containing 0.25% of Compound A.
[1200] Human gastric cancer cell line NCI-N87 purchased from ATCC (American Type Culture Collection) was suspended in DPBS (Dulbecco's phosphate-buffered saline) and cultured at 1×10 7 Each female SCID (severe combined immunodeficiency) mouse (CLEA Japan, Inc.) was subcutaneously transplanted with 100 cells into the right side (day 0). Six days later, the mice were grouped based on the estimated tumor volume. For 28 consecutive days from day 6 to day 34, compound A was orally administered as appropriate through a feed mixture containing 0.3% of compound A. On day 10, HER2-ADC (1) was intravenously administered to the tail vein at a dose of 2 mg / kg. Neither the single nor the combined administration groups showed any particularly significant findings, such as severe weight loss. The results of the combination of HER2-ADC (1) and compound A are shown in Fig.16 On day 63, the single administration of compound A showed a TGI of 38%, and the single administration of HER2-ADC (1) showed a TGI of 82%. On the other hand, the combined administration of compound A and HER2-ADC (1) showed a TGI of 97%. The combination of HER2-ADC (1) and compound A exerted a sustained superior antitumor effect compared to HER2-ADC (1) alone and compound A alone.
[1201] Example 6: Anti-tumor study (2)
[1202] The human breast cancer cell line JIMT-1 purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) was suspended in DPBS and cultured at 5×10 6 Cells were subcutaneously transplanted into the right side of each female SCID mouse (CLEA Japan, Inc.) (day 0). Fourteen days later, the mice were grouped based on the estimated tumor volume. From day 14 to day 42, compound A was orally administered as appropriate through a feed mixture containing 0.3% of compound A. On day 18, HER2-ADC (1) was intravenously administered to the tail vein at a dose of 10 mg / kg. Neither the single nor the combined administration groups showed any particularly significant findings, such as severe weight loss. The results of the combination of HER2-ADC (1) and compound A are shown in Fig.17 On day 52, the single administration of compound A showed a TGI of 19%, and the single administration of HER2-ADC (1) showed a TGI of 52%. On the other hand, the combined administration of compound A and HER2-ADC (1) showed a TGI of 94%. The combination of HER2-ADC (1) and compound A exerted a sustained superior antitumor effect compared to HER2-ADC (1) alone and compound A alone.
[1203] Example 7: Anti-tumor study (3)
[1204] The human breast cancer cell line MDA-MB-453 purchased from ATCC was suspended in 50% Matrigel matrix and cultured at 1×10 7 Cells were subcutaneously transplanted into the right side of each female SCID mouse (CLEA Japan, Inc.) (day 0). Eighteen days later, the mice were grouped based on the estimated tumor volume. From day 18 to day 46, compound A was orally administered as appropriate through a feed mixture containing 0.3% of compound A. On day 22, HER2-ADC (1) was intravenously administered to the tail vein at a dose of 1 mg / kg. Neither the single nor the combined administration groups showed any particularly significant findings, such as severe weight loss. The results of the combination of HER2-ADC (1) and compound A are shown in Fig.18 On day 74, the single administration of compound A showed a TGI of 41%, and the single administration of HER2-ADC (1) showed a TGI of 98%. On the other hand, the combined administration of compound A and HER2-ADC (1) showed a TGI of 100%. The combination of HER2-ADC (1) and compound A exerted a sustained superior antitumor effect compared to HER2-ADC (1) alone and compound A alone.
[1205] Example 8: Anti-tumor study (4)
[1206] The human breast cancer cell line MX-1 purchased from CLS (Cell Lines Service) was suspended in 50% Matrigel matrix and cultured at 5×10 6 Cells were subcutaneously transplanted into the right side of each female SCID mouse (CLEA Japan, Inc.) (day 0). Thirteen days later, the mice were grouped based on the estimated tumor volume. From day 13 to day 41, compound A was orally administered as appropriate through a feed mixture containing 0.3% of compound A. On day 17, HER2-ADC (1) was intravenously administered to the tail vein at a dose of 3 mg / kg. Neither the single nor the combined administration groups showed any particularly significant findings, such as severe weight loss. The results of the combination of HER2-ADC (1) and compound A are shown in Fig.19 On day 51, the single administration of compound A showed a TGI of 9%, and the single administration of HER2-ADC (1) showed a TGI of 70%. On the other hand, the combined administration of compound A and HER2-ADC (1) showed a TGI of 85%. The combination of HER2-ADC (1) and compound A exerted a sustained superior antitumor effect compared to HER2-ADC (1) alone and compound A alone.
[1207] Example 9: Preparation of anti-CD37 antibody-drug conjugate (1)
[1208] According to a preparation method similar to that described in Examples 1-4, an anti-CD37 antibody (an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 16 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19) was used to prepare an anti-CD37 antibody-drug conjugate (hereinafter referred to as "CD37-ADC (1)"), wherein the drug-linker represented by the following formula:
[1209] [Formula 97]
[1210]
[1211] Where A represents the connection position with the antibody,
[1212] Conjugated to anti-CD37 antibody via thioether bond. The DAR of CD37-ADC (1) is 7.8.
[1213] Example 10: Preparation of anti-B7-H3 antibody-drug conjugate (1)
[1214] According to the preparation method described in International Publication No. WO 2014 / 057687, an anti-B7-H3 antibody (an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 7 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 8) was used to prepare an anti-B7-H3 antibody-drug conjugate (hereinafter referred to as "B7-H3-ADC (1)"), wherein the drug-linker represented by the following formula:
[1215] [Formula 98]
[1216]
[1217] Where A represents the connection position with the antibody,
[1218] Conjugated to anti-B7-H3 antibody via a thioether bond. The DAR of B7-H3-ADC (1) is 4.0.
[1219] Example 11: Anti-tumor study (5)
[1220] Human breast cancer cell line ZR-75-1 purchased from ATCC (American Type Culture Collection) was suspended in Matrigel matrix and cultured at 1×10 7 Each of the cells was subcutaneously transplanted into the right side of each female NSG mouse (The Jackson Laboratory Japan, Inc.) (day 0), each of which was treated with 0.02 mg of estradiol cypionate administered subcutaneously weekly from day 0. Fourteen days later, the mice were grouped based on the estimated tumor volume. From day 14 to day 42, compound A was orally administered as appropriate through a feed mixture containing 0.3% of compound A. HER2-ADC (1) was administered intravenously to the tail vein at a dose of 5 mg / kg on day 14. Neither the single nor the combined administration groups showed any particularly significant findings, such as severe weight loss. The results of the combination of HER2-ADC (1) and compound A are shown in Fig.24 On day 49, the single administration of compound A showed a TGI of 53%, and the single administration of HER2-ADC (1) showed a TGI of 61%. On the other hand, the combined administration of compound A and HER2-ADC (1) showed a TGI of 76%. The combination of HER2-ADC (1) and compound A exerted a sustained superior antitumor effect compared to HER2-ADC (1) alone and compound A alone.
[1221] Example 12: Anti-tumor study (6)
[1222] Calu-3, a human non-small cell lung cancer cell line purchased from ATCC (American Type Culture Collection), was suspended in Matrigel matrix and cultured at 3×10 6 Cells were subcutaneously transplanted into the right side of each female SCID mouse (The Jackson Laboratory Japan, Inc.) (day 0). Fourteen days later, the mice were grouped based on the estimated tumor volume. From day 14 to day 42, compound A was orally administered as appropriate through a feed mixture containing 0.3% of compound A. On day 14, HER2-ADC (1) was intravenously administered to the tail vein at a dose of 1 mg / kg. Neither the single nor the combined administration groups showed any particularly significant findings, such as severe weight loss. The results of the combination of HER2-ADC (1) and compound A are shown in Fig.25 On day 35, the single administration of compound A showed a TGI of 20%, and the single administration of HER2-ADC (1) showed a TGI of 76%. On the other hand, the combined administration of compound A and HER2-ADC (1) showed a TGI of 95%. The combination of HER2-ADC (1) and compound A exerted a sustained superior antitumor effect compared to HER2-ADC (1) alone and compound A alone.
[1223] Example 13: Anti-tumor study (7)
[1224] Human non-small cell lung cancer cell line NCI-H358 purchased from ATCC (American Type Culture Collection) was suspended in 50% Matrigel matrix and cultured at 3×10 6 The cells were subcutaneously transplanted into the right side of each female SCID mouse (CLEA Japan, Inc.) (day 0). After 24 days, the mice were grouped based on the estimated tumor volume. From day 24 to day 66, compound A was orally administered as appropriate through a feed mixture containing 0.25% of compound A. On days 24 and 45, TROP2-ADC (1) was administered intravenously to the tail vein at a dose of 10 mg / kg. Neither the single nor the combined administration groups showed any particularly significant findings, such as severe weight loss. The results of the combination of TROP2-ADC (1) and compound A are shown in Fig.26 On day 115, the single administration of compound A showed a TGI of 20%, and the single administration of TROP2-ADC (1) showed a TGI of 78%. On the other hand, the combined administration of compound A and TROP2-ADC (1) showed a TGI of 93%. The combination of TROP2-ADC (1) and compound A exerted a sustained superior antitumor effect compared to TROP2-ADC (1) alone and compound A alone.
[1225] Example 14: Anti-tumor study (8)
[1226] Human breast cancer cell line JIMT-1 purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) was suspended in saline and cultured at 5×10 6 Cells were subcutaneously transplanted into the right side of each female SCID mouse (CLEA Japan, Inc.) (day 0). After 11 days, the mice were grouped based on the estimated tumor volume. From day 11 to day 39, compound A was orally administered as appropriate through a feed mixture containing 0.25% of compound A. HER3-ADC (1) was intravenously administered to the tail vein at a dose of 10 mg / kg on day 11. Neither the single nor the combined administration groups showed any particularly significant findings, such as severe weight loss. The results of the combination of HER3-ADC (1) and compound A are shown in Fig. 27 On day 46, the single administration of compound A showed a TGI of 41%, and the single administration of HER3-ADC (1) showed a TGI of 66%. On the other hand, the combined administration of compound A and HER3-ADC (1) showed a TGI of 77%. The combination of HER3-ADC (1) and compound A exerted a sustained superior antitumor effect compared to HER3-ADC (1) alone and compound A alone.
[1227] Example 15: Anti-tumor study (9)
[1228] The human diffuse large B-cell lymphoma cell line WSU-DLCL2 purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) was suspended in DPBS and cultured at 1×10 7 Cells were subcutaneously transplanted into the right side of each female SCID mouse (CLEA Japan, Inc.) (day 0). After 16 days, the mice were grouped based on the estimated tumor volume. From day 16 to day 44, compound A was orally administered as appropriate through a feed mixture containing 0.25% of compound A. CD37-ADC (1) was administered intravenously to the tail vein at a dose of 1 mg / kg on day 16. Neither the single nor the combined administration groups showed any particularly significant findings, such as severe weight loss. The results of the combination of CD37-ADC (1) and compound A are shown in Fig.28On day 44, the single administration of compound A showed a TGI of 31%, and the single administration of CD37-ADC (1) showed a TGI of 43%. On the other hand, the combined administration of compound A and CD37-ADC (1) showed a TGI of 78%. The combination of CD37-ADC (1) and compound A exerted a sustained superior antitumor effect compared to CD37-ADC (1) alone and compound A alone.
[1229] Example 16: Anti-tumor study (10)
[1230] Human neuroendocrine prostate cancer cell line NCI-H660 purchased from ATCC (American Type Culture Collection) was suspended in 50% Matrigel matrix and cultured at 2×10 6 Each of the cells was subcutaneously transplanted into the right side of castrated male SCID mice (CLEA Japan, Inc.) (day 0). After 29 days, the mice were grouped based on the estimated tumor volume. From day 29 to day 58, compound A was orally administered as appropriate through a feed mixture containing 0.25% of compound A. B7-H3-ADC (1) was intravenously administered to the tail vein at a dose of 0.3 mg / kg on days 29 and 43. Neither the single nor the combined administration groups showed any particularly significant findings, such as severe weight loss. The results of the combination of B7-H3-ADC (1) and compound A are shown in Fig.29 On day 58, the single administration of compound A showed a TGI of 80%, and the single administration of B7-H3-ADC (1) showed a TGI of 37%. On the other hand, the combined administration of compound A and B7-H3-ADC (1) showed a TGI of 91%. The combination of B7-H3-ADC (1) and compound A exerted a sustained superior antitumor effect compared to B7-H3-ADC (1) alone and compound A alone.
[1231] Free text for sequence listings
[1232] SEQ ID NO: 1—Amino acid sequence of the heavy chain of an anti-HER2 antibody
[1233] SEQ ID NO:2—Amino acid sequence of the light chain of an anti-HER2 antibody
[1234] SEQ ID NO:3—Amino acid sequence of the heavy chain of an anti-HER3 antibody
[1235] SEQ ID NO:4—Amino acid sequence of the light chain of an anti-HER3 antibody
[1236] SEQ ID NO:5—Amino acid sequence of the heavy chain of an anti-TROP2 antibody
[1237] SEQ ID NO:6—Amino acid sequence of the light chain of an anti-TROP2 antibody
[1238] SEQ ID NO:7—Amino acid sequence of the heavy chain of anti-B7-H3 antibody
[1239] SEQ ID NO:8—Amino acid sequence of the light chain of the anti-B7-H3 antibody
[1240] SEQ ID NO:9—Amino acid sequence of the heavy chain of an anti-GPR20 antibody
[1241] SEQ ID NO: 10 - Amino acid sequence of the light chain of an anti-GPR20 antibody
[1242] SEQ ID NO: 11 - Amino acid sequence of the heavy chain of anti-CDH6 antibody
[1243] SEQ ID NO: 12 - Amino acid sequence of the light chain of an anti-CDH6 antibody
[1244] SEQ ID NO: 13 - Amino acid sequence of the heavy chain of anti-MUC1 antibody (N54Q)
[1245] SEQ ID NO: 14—Amino acid sequence of the heavy chain of anti-MUC1 antibody (PankoMab)
[1246] SEQ ID NO:15—Amino acid sequence of the light chain of anti-MUC1 antibodies (N54Q and PankoMab)
[1247] SEQ ID NO: 16 - Amino acid sequence of the heavy chain of anti-CD37 antibody (hmAb-H541)
[1248] SEQ ID NO: 17 - Amino acid sequence of the heavy chain of anti-CD37 antibody (hmAb-H551)
[1249] SEQ ID NO: 18 - Amino acid sequence of the heavy chain of anti-CD37 antibody (hmAb-H11a)
[1250] SEQ ID NO: 19 - Amino acid sequence of the light chain of anti-CD37 antibody (hmAb-L11)
[1251] SEQ ID NO:20—Amino acid sequence of CDRH1 of the heavy chain of an anti-HER2 antibody
[1252] SEQ ID NO:21 - Amino acid sequence of CDRH2 of the heavy chain of an anti-HER2 antibody
[1253] SEQ ID NO:22—Amino acid sequence of CDRH3 of the heavy chain of an anti-HER2 antibody
[1254] SEQ ID NO:23—Amino acid sequence of CDRL1 of the light chain of an anti-HER2 antibody
[1255] SEQ ID NO:24—Amino acid sequence of CDRL2 of the light chain of an anti-HER2 antibody
[1256] SEQ ID NO:25—Amino acid sequence of CDRL3 of the light chain of an anti-HER2 antibody
[1257] SEQ ID NO:26—Amino acid sequence of the heavy chain variable region of an anti-HER2 antibody
[1258] SEQ ID NO:27—Amino acid sequence of the light chain variable region of an anti-HER2 antibody
[1259] SEQ ID NO:28—Amino acid sequence of CDRH1 of the heavy chain of anti-TROP2 antibody
[1260] SEQ ID NO:29—Amino acid sequence of CDRH2 of the heavy chain of an anti-TROP2 antibody
[1261] SEQ ID NO:30—Amino acid sequence of CDRH3 of the heavy chain of an anti-TROP2 antibody
[1262] SEQ ID NO:31 - Amino acid sequence of CDRL1 of the light chain of an anti-TROP2 antibody
[1263] SEQ ID NO:32 - Amino acid sequence of CDRL2 of the light chain of an anti-TROP2 antibody
[1264] SEQ ID NO:33 - Amino acid sequence of CDRL3 of the light chain of an anti-TROP2 antibody
[1265] SEQ ID NO:34 - Amino acid sequence of the heavy chain variable region of an anti-TROP2 antibody
[1266] SEQ ID NO:35—Amino acid sequence of the light chain variable region of an anti-TROP2 antibody.
Claims
1. A pharmaceutical product comprising an antibody-drug conjugate for combined administration and an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor and an EZH1 / 2 dual inhibitor, wherein The antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker is represented by the following formula: [Formula 99] Where A represents the connection position with the antibody, Conjugation to the antibody is via a thioether bond.
2. The drug product according to claim 1, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody, an anti-MUC1 antibody or an anti-CD37 antibody.
3. The pharmaceutical product according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
4. The pharmaceutical product according to claim 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO: 1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO: 1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO: 1; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO: 2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO: 2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:
2.
5. The pharmaceutical product according to claim 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO: 1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:
2.
6. The pharmaceutical product according to claim 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 1, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:
2.
7. The pharmaceutical product according to claim 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO: 1; and the light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:
2.
8. The pharmaceutical product according to any one of claims 3 to 7, wherein the antibody-drug conjugate is represented by the following formula: [Formula 100] wherein "antibody" indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
9. The pharmaceutical product according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
10. The pharmaceutical product according to claim 9, wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 35 of SEQ ID NO:3, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 50 to 65 of SEQ ID NO:3, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 98 to 106 of SEQ ID NO:3; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 24 to 39 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 56 to 62 of SEQ ID NO:4, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 95 to 103 of SEQ ID NO:
4.
11. The pharmaceutical product according to claim 9, wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 117 of SEQ ID NO:3; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO:
4.
12. The pharmaceutical product according to claim 9, wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:3, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:
4.
13. The pharmaceutical product according to claim 12, wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
14. The pharmaceutical product according to any one of claims 9 to 13, wherein the antibody-drug conjugate is represented by the following formula: [Formula 101] wherein "antibody" indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
15. The pharmaceutical product according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
16. The pharmaceutical product according to claim 15, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:
6.
17. The pharmaceutical product according to claim 15, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:
6.
18. The pharmaceutical product according to claim 15, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
6.
19. The pharmaceutical product according to claim 18, wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
20. The pharmaceutical product according to any one of claims 15 to 19, wherein the antibody-drug conjugate is represented by the formula: [Formula 102] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.
5.
21. The pharmaceutical product according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
22. The pharmaceutical product according to claim 21, wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:
8.
23. The pharmaceutical product according to claim 22, wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
24. A pharmaceutical product according to any one of claims 21 to 23, wherein the antibody-drug conjugate is represented by the formula: [Formula 103] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.
5.
25. The pharmaceutical product according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
26. The pharmaceutical product according to claim 25, wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
10.
27. The pharmaceutical product according to claim 26, wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
28. A pharmaceutical product according to any one of claims 25 to 27, wherein the antibody-drug conjugate is represented by the formula: [Formula 104] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
29. The drug product according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
30. The pharmaceutical product according to claim 29, wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 11; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:
12.
31. The pharmaceutical product according to claim 30, wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
32. A pharmaceutical product according to any one of claims 29 to 31, wherein the antibody-drug conjugate is represented by the formula: [Formula 105] wherein "antibody" indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
33. The drug product according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-MUCl antibody.
34. The pharmaceutical product according to claim 33, wherein the anti-MUCl antibody is an antibody comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO:13 and a light chain consisting of the amino acid sequence shown in SEQ ID NO:
15.
35. The pharmaceutical product according to claim 34, wherein the anti-MUCl antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
36. The pharmaceutical product according to claim 33, wherein the anti-MUCl antibody is an antibody comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14 and a light chain consisting of the amino acid sequence shown in SEQ ID NO:
15.
37. The pharmaceutical product according to claim 36, wherein the anti-MUCl antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
38. A pharmaceutical product according to any one of claims 33 to 37, wherein the antibody-drug conjugate is represented by the formula: [Equation 106] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
39. The pharmaceutical product according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-CD37 antibody.
40. The pharmaceutical product according to claim 39, wherein the anti-CD37 antibody is an antibody selected from the group consisting of: (a) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 16; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19, (b) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 17; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19, and (c) An antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO:18; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO:
19.
41. The pharmaceutical product according to claim 39, wherein the anti-CD37 antibody is an antibody selected from the group consisting of: (d) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 16; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19, (e) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 17; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19, and (f) An antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
19.
42. The pharmaceutical product according to claim 39, wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 16; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
19.
43. The pharmaceutical product according to claim 42, wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
44. A pharmaceutical product according to claim 42 or claim 43, wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
45. The pharmaceutical product according to claim 39, wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 17; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
19.
46. A pharmaceutical product according to claim 45, wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
47. A pharmaceutical product according to claim 45 or claim 46, wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
48. A pharmaceutical product according to claim 39, wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 18; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
19.
49. The pharmaceutical product according to claim 48, wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
50. A pharmaceutical product according to claim 48 or claim 49, wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
51. A pharmaceutical product according to any one of claims 39 to 50, wherein the antibody-drug conjugate is represented by the formula: [Equation 107] wherein "antibody" indicates an anti-CD37 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
52. The pharmaceutical product according to any one of claims 1 to 8, wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
53. The pharmaceutical product according to any one of claims 1, 2 and 15 to 20, wherein the antibody-drug conjugate is dedabrizumab (DS-1062).
54. A pharmaceutical product according to any one of claims 1 to 53, wherein the inhibitor is an EZH2 inhibitor.
55. The pharmaceutical product according to claim 54, wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
56. A pharmaceutical product according to any one of claims 1 to 53, wherein the inhibitor is an EZH1 / 2 dual inhibitor.
57. The pharmaceutical product according to claim 56, wherein the inhibitor is vametocastat or a pharmaceutically acceptable salt thereof.
58. A pharmaceutical product according to claim 56 or claim 57, wherein the inhibitor is valmetostostat tosylate.
59. The pharmaceutical product according to any one of claims 1 to 58, wherein the antibody-drug conjugate and the inhibitor are contained as active ingredients in different formulations, respectively, and are administered simultaneously or at different times.
60. The pharmaceutical product according to any one of claims 1 to 59, wherein the pharmaceutical product is for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumors, renal cancer and sarcoma.
61. The pharmaceutical product according to claim 60, wherein the pharmaceutical product is for use in the treatment of breast cancer.
62. The pharmaceutical product according to claim 61, wherein the pharmaceutical product is for use in the treatment of triple negative breast cancer.
63. The pharmaceutical product according to claim 60, wherein the pharmaceutical product is for use in the treatment of gastric cancer.
64. The pharmaceutical product according to claim 60, wherein the pharmaceutical product is for use in the treatment of ovarian cancer.
65. The pharmaceutical product according to claim 60, wherein the pharmaceutical product is for use in the treatment of lung cancer.
66. The pharmaceutical product according to claim 60, wherein the pharmaceutical product is for use in the treatment of pancreatic cancer.
67. An antibody-drug conjugate for use in a method of treating a disease, wherein the method comprises administering the antibody-drug conjugate in combination with an inhibitor selected from an EZH1 inhibitor, an EZH2 inhibitor, and an EZH1 / 2 dual inhibitor, wherein the antibody-drug conjugate is an antibody-drug conjugate wherein the drug-linker represented by the following formula in the antibody-drug conjugate: [Formula 108] Where A represents the connection position with the antibody, Conjugation to the antibody is via a thioether bond.
68. The antibody-drug conjugate for use according to claim 67, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, an anti-CDH6 antibody, an anti-MUC1 antibody or an anti-CD37 antibody.
69. The antibody-drug conjugate for use according to claim 68, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
70. An antibody-drug conjugate for use according to claim 69, wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 33 of SEQ ID NO:1, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 51 to 58 of SEQ ID NO:1, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 97 to 109 of SEQ ID NO:1; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 27 to 32 of SEQ ID NO:2, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 50 to 52 of SEQ ID NO:2, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 89 to 97 of SEQ ID NO:
2.
71. An antibody-drug conjugate for use according to claim 69, wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 120 of SEQ ID NO: 1; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 107 of SEQ ID NO:
2.
72. The antibody-drug conjugate for use according to claim 69, wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 1, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:
2.
73. An antibody-drug conjugate for use according to claim 69, wherein the anti-HER2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO:1, and the light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO:
2.
74. An antibody-drug conjugate for use according to any one of claims 69 to 73, The antibody-drug conjugate is represented by the following formula: [Equation 109] wherein "antibody" indicates an anti-HER2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
75. The antibody-drug conjugate for use according to claim 68, wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
76. An antibody-drug conjugate for use according to claim 75, wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 26 to 35 of SEQ ID NO:3, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 50 to 65 of SEQ ID NO:3, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 98 to 106 of SEQ ID NO:3; and the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 24 to 39 of SEQ ID NO:4, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 56 to 62 of SEQ ID NO:4, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 95 to 103 of SEQ ID NO:
4.
77. An antibody-drug conjugate for use according to claim 75, wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 117 of SEQ ID NO:3; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 1 to 113 of SEQ ID NO:
4.
78. The antibody-drug conjugate for use according to claim 75, wherein the anti-HER3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of the amino acid sequence shown in SEQ ID NO:3, and the light chain consisting of the amino acid sequence shown in SEQ ID NO:
4.
79. The antibody-drug conjugate for use according to claim 78, wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
80. An antibody-drug conjugate for use according to any one of claims 75 to 79, wherein the antibody-drug conjugate is represented by the following formula: [Formula 110] wherein "antibody" indicates an anti-HER3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
81. The antibody-drug conjugate for use according to claim 68, wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
82. An antibody-drug conjugate for use according to claim 81, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising CDRH1 consisting of an amino acid sequence consisting of amino acid residues 50 to 54 of SEQ ID NO:5, CDRH2 consisting of an amino acid sequence consisting of amino acid residues 69 to 85 of SEQ ID NO:5, and CDRH3 consisting of an amino acid sequence consisting of amino acid residues 118 to 129 of SEQ ID NO:5; the light chain comprising CDRL1 consisting of an amino acid sequence consisting of amino acid residues 44 to 54 of SEQ ID NO:6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 70 to 76 of SEQ ID NO:6, and CDRL3 consisting of an amino acid sequence consisting of amino acid residues 109 to 117 of SEQ ID NO:
6.
83. An antibody-drug conjugate for use according to claim 81, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 140 of SEQ ID NO:5; and the light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 129 of SEQ ID NO:
6.
84. An antibody-drug conjugate for use according to claim 81, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:5; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
6.
85. The antibody-drug conjugate for use according to claim 84, wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
86. An antibody-drug conjugate for use according to any one of claims 81 to 85, wherein the antibody-drug conjugate is represented by the following formula: [Formula 111] wherein "antibody" indicates an anti-TROP2 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.
5.
87. The antibody-drug conjugate for use according to claim 68, wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
88. An antibody-drug conjugate for use according to claim 87, wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:7; and the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:
8.
89. The antibody-drug conjugate for use according to claim 88, wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
90. An antibody-drug conjugate for use according to any one of claims 87 to 89, wherein the antibody-drug conjugate is represented by the following formula: [Formula 112] wherein "antibody" indicates an anti-B7-H3 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 3.5 to 4.
5.
91. The antibody-drug conjugate for use according to claim 68, wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
92. An antibody-drug conjugate for use according to claim 91, wherein the anti-GPR20 antibody is an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO:9; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
10.
93. The antibody-drug conjugate for use according to claim 92, wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
94. An antibody-drug conjugate for use according to any one of claims 91 to 93, wherein the antibody-drug conjugate is represented by the following formula: [Formula 113] wherein "antibody" indicates an anti-GPR20 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
95. The antibody-drug conjugate for use according to claim 68, wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.
96. An antibody-drug conjugate for use according to claim 95, wherein the anti-CDH6 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO:11; the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO:
12.
97. The antibody-drug conjugate for use according to claim 96, wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
98. An antibody-drug conjugate for use according to any one of claims 95 to 97, wherein the antibody-drug conjugate is represented by the formula: [Formula 114] wherein "antibody" indicates an anti-CDH6 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
99. The antibody-drug conjugate for use according to claim 68, wherein the antibody in the antibody-drug conjugate is an anti-MUCl antibody.
100. The antibody-drug conjugate for use according to claim 99, wherein the anti-MUC1 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 13 and a light chain consisting of the amino acid sequence shown in SEQ ID NO:
15.
101. The antibody-drug conjugate for use according to claim 100, wherein the anti-MUCl antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
102. The antibody-drug conjugate for use according to claim 99, wherein the anti-MUC1 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO:14 and a light chain consisting of the amino acid sequence shown in SEQ ID NO:
15.
103. The antibody-drug conjugate for use according to claim 102, wherein the anti-MUCl antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.
104. An antibody-drug conjugate for use according to any one of claims 99 to 103, wherein the antibody-drug conjugate is represented by the formula: [Formula 115] wherein "antibody" indicates an anti-MUC1 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n ranges from 7 to 8.
105. The antibody-drug conjugate for use according to claim 68, wherein the antibody in the antibody-drug conjugate is an anti-CD37 antibody.
106. The antibody-drug conjugate for use according to claim 105, wherein the anti-CD37 antibody is an antibody selected from the group consisting of: (a) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 16; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19, (b) an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO: 17; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO: 19, and (c) An antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 138 of SEQ ID NO:18; and the light chain comprises a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of SEQ ID NO:
19.
107. The antibody-drug conjugate for use according to claim 105, wherein the anti-CD37 antibody is an antibody selected from the group consisting of: (d) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 16; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19, (e) an antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 17; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 19, and (f) An antibody comprising a heavy chain and a light chain, wherein the heavy chain consists of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:18; and the light chain consists of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
19.
108. An antibody-drug conjugate for use according to claim 105, wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 16; the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
19.
109. The antibody-drug conjugate for use according to claim 108, wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
110. The antibody-drug conjugate for use according to claim 108 or claim 109, wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
111. An antibody-drug conjugate for use according to claim 105, wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 17; the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
19.
112. The antibody-drug conjugate for use according to claim 111, wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
113. An antibody-drug conjugate for use according to claim 111 or claim 112, wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
114. An antibody-drug conjugate for use according to claim 105, wherein the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO: 18; the light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:
19.
115. The antibody-drug conjugate for use according to claim 114, wherein the anti-CD37 antibody lacks 1 or 2 amino acid residues at the carboxyl terminus of the heavy chain.
116. An antibody-drug conjugate for use according to claim 114 or claim 115, wherein the proline residue at the carboxyl terminus of the heavy chain is amidated.
117. An antibody-drug conjugate for use according to any one of claims 105 to 116, wherein the antibody-drug conjugate is represented by the following formula: [Formula 116] wherein "antibody" indicates an anti-CD37 antibody conjugated to a drug-linker via a thioether bond, and n indicates the average number of drug-linker units conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of 7 to 8.
118. The antibody-drug conjugate for use according to any one of claims 67 to 74, wherein the antibody-drug conjugate is trastuzumab (DS-8201a).
119. The antibody-drug conjugate for use according to any one of claims 67 to 68 and 81 to 86, wherein the antibody-drug conjugate is dedabruzumab (DS-1062).
120. The antibody-drug conjugate for use according to any one of claims 67 to 119, wherein the inhibitor is an EZH2 inhibitor.
121. The antibody-drug conjugate for use according to claim 120, wherein the inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
122. An antibody-drug conjugate for use according to any one of claims 67 to 119, wherein the inhibitor is an EZH1 / 2 dual inhibitor.
123. The antibody-drug conjugate for use according to claim 122, wherein the inhibitor is vametocastat or a pharmaceutically acceptable salt thereof.
124. An antibody-drug conjugate for use according to claim 122 or claim 123, wherein the inhibitor is valmetostostat tosylate.
125. The antibody-drug conjugate for use according to any one of claims 67 to 124, wherein the antibody-drug conjugate and the inhibitor are contained in different preparations as active components, respectively, and are administered simultaneously or at different times.
126. An antibody-drug conjugate for use according to any one of claims 67 to 125, wherein the disease is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumors, renal cancer and sarcoma.
127. The antibody-drug conjugate for use according to claim 126, wherein the disease is breast cancer.
128. The antibody-drug conjugate for use according to claim 127, wherein the disease is triple negative breast cancer.
129. The antibody-drug conjugate for use according to claim 126, wherein the disease is gastric cancer.
130. The antibody-drug conjugate for use according to claim 126, wherein the disease is ovarian cancer.
131. The antibody-drug conjugate for use according to claim 126, wherein the disease is lung cancer.
132. The antibody-drug conjugate for use according to claim 126, wherein the disease is pancreatic cancer.
